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“The important thing is to not stop questioning. Curiosity has its own reason 
for existence.  One cannot help but be in awe when he contemplates the 
mysteries of eternity, of life, of the marvelous structure of reality.  It is 
enough if one tries merely to comprehend a little of this mystery each day.” 
 
—"Old Man's Advice to Youth: 'Never Lose a Holy Curiosity.'" LIFE 
Magazine (2 May 1955) p. 64”  
― Albert Einstein 
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Abstract 
Introduction: HIV infection is characterized by CD4+ T cell immunodeficiency and 
chronic inflammation. Antiretroviral therapy (ART) leads to the recovery of CD4+ T 
cells by suppressing viral replication. However 15-30% of HIV-infected ART-treated 
patients fail to restore CD4+ T cells despite full viral suppression and they are 
known as “Immunological Non-Responders (INR)”. INRs are characterized by 
higher risk of AIDS progression and non-AIDS-related morbidity compared to HIV-
infected ART-treated immunological responder (IR) patients. Several mechanisms 
have been involved in immune failure, however none of them provides a full 
explanation for the lack of immune reconstitution observed in INRs. 
Inflammasomes are multimeric protein platforms involved in the regulation of 
inflammatory responses, Th17 activity and in a high inflammatory form of 
programmed cell-death called “pyroptosis”. Pyroptosis was recently shown to play 
a major role in CD4+ T cell loss and to contribute to immune activation in HIV 
infection. The possible role of inflammasomes and pyroptosis in the lack of immune 
reconstitution has nevertheless not been investigated. We analyzed possible 
associations between inflammasome and Th17 activity, caspase-1 activation, 
pyroptosis and immune reconstitution in HIV-infected ART treated patients. 
Methods: 39 HIV-infected patients on antiretroviral therapy for ≥24 months and 
plasma HIV-RNA<50cp/mL for ≥12 months, matched for nadir CD4+ T cell count 
were enrolled. Exclusion criteria: presence of actual opportunistic AIDS-related 
diseases, HBV or HCV co-infection, chronic inflammatory disorders, ongoing 
immunosuppressive therapy. Patients were classified as IRs or INRs if CD4+ T cell 
count was ≥500 or ≤350 cells/µL, respectively. Immune activation markers (HLA-
DRII and CD38) and Th17 activity were evaluated by flow cytometry. Expression of 
genes involved in the inflammasome pathway and in pyroptosis were measured in 
unstimulated or LPS- and AT2 treated-HIV-1-stimulated cells. Pro-inflammatory 
cytokines, caspase-1 expression and microbial translocation markers (sCD14 and 
LPS) were quantified in plasma samples of all IRs and INRs.  
Results: INR patients were older and had a higher prevalence of past AIDS-
defining illnesses. HLADRII/CD4 were significantly increased in INRs. Higher 
median levels of Th17 T cells (CD4/IL17A/RORγT) were also seen in INRs in 
unstimulated, as well as in LPS- and AT2 treated-HIV-1 stimulated conditions. 
LPS-stimulated inflammasome (NLRP3) and pro-inflammatory cytokines gene 
expression (IL-1β, IL-18, TNFα, type-I IFNs, CCL3, IL-6) were significantly 
increased in INR patients. AT2-HIV-1 stimulation induced NLRP3 gene expression 
in both IRs and INRs; NLRP3 and IL-18 expression were nevertheless significantly 
increased in INRs compared to IRs. Higher caspase-1gene expression was seen in 
both unstimulated and AT2-HIV-1 stimulated cells of INRs, whereas caspase 3, 4 
and 5 expression was similar in both groups. Plasma concentration of caspase-1 
and IL-1βwere higher in INR compared to IR patients. No differences in microbial 
translocation markers could be detected between the two groups.  
Conclusions: Increased immune activation levels and percentage of Th17 T cells 
and higher levels of inflammasome and caspase-1 expression are observed in INR 
patients. The upregulation of these pro-inflammatory mechanisms plausibly 
contributes to the persistent immune activation that characterize INRs. Notably, 
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caspase-1 activation is likely to induce CD4+ T cell loss via pyroptosis, contributing 
to the unsatisfactory CD4+ T cell recovery seen in INRs. 
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Sommario 
Introduzione: La caratterista principale dell’infezione da HIV è lo sviluppo di una 
immunodeficienza dovuta alla perdita dei linfociti T CD4+. Inoltre, l’infezione da HIV 
si caratterizza anche per marcati livelli di infiammazione cronica e immuno-
attivazione. La terapia antiretrovirale (ART) impedisce la replicazione virale 
permettendo così il recupero dei linfociti T CD4+. Nonostante ciò, in una 
percentuale variabile fra il 15 e il 30% dei pazienti HIV infetti e sotto terapia 
antiretrovirale, non si osserva il recupero delle cellule T CD4+, nonostante la 
completa soppressione della carica virale. Proprio per questa caratteristica, questi 
pazienti sono chiamati “Immunological Non-Responders (Immunologicamente non-
rispondenti” (INRs). Gli INRs sono pazienti soggetti a un maggior rischio di 
progressione della malattia verso AIDS conclamata e allo sviluppo di morbidità 
legate all’AIDS rispetto a pazienti HIV infetti e in terapia antiretrovirale che però 
presentano un recupero immunologico. Diversi meccanismi biologici sono stati 
associati al fallimento immunologico della ART, tuttavia nessuno di questi è in 
grado di spiegare in maniera esaustiva i motivi del mancato recupero 
immunologico che si osserva negli INRs. Gli inflammasomi sono piattaforme 
proteiche coinvolte nella regolazione delle risposte infiammatorie, nell’attività dei 
linfociti Th17 e in una forma altamente infiammatoria di morte cellulare 
programmata chiamata “piroptosi”. Recentemente, alcuni studi hanno dimostrato 
che la piroptosi gioca un ruolo importante nella morte dei linfociti CD4+ e che 
potrebbe anche contribuire all’attivazione immunitaria associata all’infezione da 
HIV. Il ruolo degli inflammasomi e della piroptosi nel mancato recupero 
immunologico non sono stati, tuttavia, ancora stati studiati. Per questo motivo 
abbiamo analizzato le possibili associazioni fra l’attivazione dell’inflammasoma, 
della caspasi 1, della piroptosi e dell’attività dei Th17 e la ricostituzione immunitaria 
in pazienti sieropositivi e sotto terapia antiretrovirale.  
Metodi: Sono stati arruolati 39 pazienti HIV infetti e in terapia antiretrovirale da più 
di 24 mesi, con viremia soppressa (HIV-RNA<50cp/mL da più di 12 mesi) e con 
comparabile nadir dei linfociti CD4+. I criteri di esclusione sono stati i seguenti: 
presenza di infezioni opportunistiche correlate ad AIDS, confezioni da HBV o da 
HCV, malattie infiammatorie croniche e terapia immunosoppressiva in corso. I 
pazienti sono stati classificati come “Immunological Responders” (IR) con conta di 
linfociti T CD4+ ≥500 cellule/μl o come “Immunological Non-Responders” con 
conta dei linfociti ≤350 cellule/μl. I marker di attivazione immunitaria (HLA-DRII e 
CD38) e l’attività dei linfociti Th17 sono stati valutati tramite citofluorimetria a 
flusso. L’espressione di geni coinvolti nel pathway degli inflammasomi e della 
piroptosi è stata valutata in cellule non-stimolate o stimolate rispettivamente con 
LPS o HIV-1 inattivato da AT2 (AT2-HIV). A livello plasmatico sono stati quantificati 
i livelli di citochine pro infiammatorie, della caspasi 1 e della traslocazione 
microbica (sCD14 e LPS).  
Risultati: I pazienti INRs erano più anziani e avevano una maggiore prevalenza di 
malattie legate all’AIDS. I linfociti CD4+ positivi per HLADRII sono 
significativamente aumentati negli INRs. Inoltre, negli INRs sono stati osservati 
anche maggiori livelli di espressione dei linfociti Th17 (CD4/IL17A/RORγT) sia in 
assenza di stimolazione, sia in seguito a stimolazione con LPS o con HIV. Negli 
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INRs è stato osservato un aumento dell’espressione dell’inflammosoma (NLRP3) e 
di diverse citochine pro-infiammatorie (IL-1β, IL-18, TNFα, type-I IFNs, CCL3, IL-6) 
in seguito a stimolazione con LPS. La stimolazione con AT2-HIV è in grado di 
indurre l’espressione di NLRP3 sia negli IRs sia negli INRs, tuttavia in quest’ultimi, 
l’espressione di NLRP3 e dell’IL-18 risulta significativamente aumentata rispetto 
agli IRs. Negli INRs si è osservato anche un aumento dell’espressione genica della 
caspasi-1 sia in assenza di stimolazione sia in seguito a stimolazione con AT2-HIV, 
mentre invece l’espressione delle caspasi 3, 4 e 5 è simile in entrambi i gruppi. Le 
concentrazioni plasmatiche della caspasi-1 e della IL-1β sono più alte negli INRs 
rispetto agli IRs. Non abbiamo riscontrato nessuna differenza nell’espressione di 
marcatori di traslocazione microbica fra i due gruppi di pazienti.  
Conclusioni: Nei pazienti INRs abbiamo osservato un aumento dell’immuno-
attivazione, delle percentuali di linfociti Th17 periferici e dell’espressione della 
caspasi-1 e di NLRP3. E’ plausibile ipotizzare che l’aumento di espressione di 
queste meccanismi pro-infiammatori contribuisca in maniera significativa 
all’immuno-attivazione che caratterizza gli INRs. La caspasi-1 è in grado di indurre 
la morte dei linfociti T CD4+ tramite piroptosi e, pertanto, è possibile ipotizzare che 
l’aumentata espressione negli INRs contribuisca al mancato recupero 
immunologico osservato in questi pazienti. 
 7 
 
Table of Contents 
ABSTRACT ............................................................................................... III 
SOMMARIO ............................................................................................... V 
TABLE OF CONTENTS ............................................................................. 7 
LIST OF ABBREVIATIONS ...................................................................... 11 
INTRODUCTION ...................................................................................... 13 
1. HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED 
IMMUNODEFICIENCY SYNDROME (AIDS) ................................................... 14 
1.1 HIV-1 Virology ........................................................................ 14 
1.1.1 HIV Classification .................................................................. 14 
1.1.2 HIV Genome and Structure ................................................... 15 
1.1.3 HIV Life Cycle ........................................................................ 17 
1.2 HIV Pathogenesis ....................................................................... 20 
2. HIV IMMUNOLOGY ............................................................................... 23 
2.1 Immune responses to HIV ......................................................... 23 
2.1.1 Innate Immune Response ...................................................... 23 
2.1.2 Cellular Immune Response ................................................... 24 
2.1.3 Humoral Immune Response .................................................. 26 
2.2 Immune Activation in chronic HIV infection ............................. 27 
2.2.1 Mechanisms of Immune Activation and Microbial Translocation
 ....................................................................................................... 28 
2.2.2 Immune Activation and HIV Pathogenesis ............................. 33 
3. HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) AND IMMUNE 
RECONSTITUTION .................................................................................... 34 
3.1 Immune reconstitution in HAART ............................................. 37 
3.2 Immune Failure in HAART: Immunological Non-Responders 
(INRs) ................................................................................................ 41 
 8 
 
3.2.1 Failures in the production of CD4+ T Cells in INRs ................. 44 
3.2.2 Excessive destruction of CD4+ T Cells in INRs ...................... 46 
4. INFLAMMASOMES AND HIV PATHOGENESIS ........................................... 49 
4.1 Inflammasomes .......................................................................... 49 
4.1.1 NLR Family ............................................................................ 51 
4.1.1.1 NLRP1 ................................................................................ 53 
4.1.1.2 NLRP3: canonical and non canonicalinflammasome .......... 54 
4.1.1.3 NLRC4 ............................................................................... 57 
4.1.1.4 AIM2 and Pyrin ................................................................... 57 
4.2 Inflammasomes and T Cell Responses .................................... 58 
4.3 Pyroptosis .................................................................................. 59 
4.4 Inflammasomes, pyroptosis and HIV pathogenesis ................ 60 
4.4.1 Inflammasomes and HIV-1 .................................................... 60 
4.4.2 Pyroptosis and HIV ................................................................ 62 
AIM OF THE STUDY ................................................................................ 68 
MATERIALS AND METHODS .................................................................. 70 
1. SAMPLE COLLECTION .......................................................................... 71 
1.1 Study Population ....................................................................... 71 
1.2 PBMCs Separation ..................................................................... 71 
1.2.1 Cell Count.............................................................................. 72 
1.3 PBMCs Cell Culture and Stimulation ........................................ 73 
2. FLOW CYTOMETRY ANALYSIS .............................................................. 74 
2.1 Immunophenotypic analysis ..................................................... 74 
2.2 Intracellular Cytokine Staining and T cell subsets detection.. 75 
3. GENE EXPRESSION ANALYSIS .............................................................. 76 
3.1 Total RNA Extraction ................................................................. 76 
3.2 DNAse treatment ........................................................................ 77 
3.3 Retrotranscription ...................................................................... 77 
3.4 Real-Time PCR Array ................................................................. 78 
 9 
 
3.5 Real-Time PCR ........................................................................... 80 
4. ELISA ASSAYS .................................................................................... 82 
4.1 Plasma LPS quantification ........................................................ 82 
4.2 Plasma sCD14 quantification .................................................... 83 
4.3 Plasma IL-18 Quantification ...................................................... 84 
4.4 Plasma IL-1β Quantification ...................................................... 84 
4.5 Plasma IL-6 Quantification ........................................................ 86 
4.6 Plasma Caspase-1 Quantification ............................................. 87 
5. STATISTICAL ANALYSIS ....................................................................... 87 
RESULTS ................................................................................................. 88 
1. STUDY POPULATION ............................................................................ 89 
2. T-CELL IMMUNE ACTIVATION ................................................................ 91 
3. NLRP3 INFLAMMASOME ACTIVATION ................................................... 93 
3.1 NLRP3 expression in unstimulated PBMCs ............................. 93 
3.2. Inflammasome Pathway Gene Expression .............................. 94 
3.2.1 Inflammasome Pathway Gene Expression in LPS-stimulated 
PBMCs ........................................................................................... 95 
3.2.2 Gene Expression Profile in LPS-stimulated PBMCs .............. 97 
3.2.3 Inflammasome Pathway Gene Expression in AT2-treated HIV-
1BaL-stimulated PBMCs ................................................................... 98 
3.2.4 Gene Expression Profile in AT2-treated HIV-1BaL-stimulated 
PBMCs ......................................................................................... 100 
4. CASPASES, IFI16 AND PRO-INFLAMMATORY CYTOKINES EXPRESSION 
PROFILE ............................................................................................... 102 
5. PERIPHERAL TH17 T-CELLS EVALUATION IN IRS AND INRS ................. 109 
6. MICROBIAL TRANSLOCATION ............................................................. 111 
DISCUSSION ......................................................................................... 113 
CONCLUSIONS ..................................................................................... 122 
 10 
 
REFERENCES ....................................................................................... 124 
SCIENTIFIC PRODUCTS ....................................................................... 160 
PUBLICATIONS ...................................................................................... 161 
ABSTRACTS .......................................................................................... 162 
AWARDS .............................................................................................. 166 
ACKNOWLEDGMENTS ......................................................................... 167 
 
 
  
 11 
 
List of Abbreviations 
3TC: Lamivudine  
ABC: Abacavir 
AIDS: Acquired Immunodeficiency Syndrome 
ART: Antiretroviral therapy 
ART: Antiretroviral Therapy 
ASC: Apoptosis-associated speck-like protein 
AT2: Aldrithiol 2 
AZT: Atazanavir, 
CARD: Caspase recruitment domain 
CCR: C-C Chemokine Receptor  
CD: Cluster of Differentiation 
CTL: cytotoxic lymphocyte 
CXCR: C-X-C Chemokine Receptor  
d4T: Stavudina 
DAMP: Danger-associated molecular pattern 
DC: Dedritic cell 
DRV: Darunavir 
dsRNA: Double-strand RNA 
EFV: Efavirenz 
ENF: Enfuvirtide 
FIs: Fusion Inhibitors  
FPV: Fosamprenavir 
FTC: Emtricitabine 
GALT: Gut-Associated Lymphoid Tissue 
GBP: Guanylate-binding proteins 
GM-CSF: Granulocyte-macrophage colony-stimulating factor also known as 
colony stimulating factor 
GSDMD: Gasdermin D protein 
HAART: Highly Active Antiretroviral Therapy 
HIV: Human Immunodeficiency Virus 
HLA: human leukocyte antigen 
HLAC: Human lymphoid aggregate culture 
HLA-DR: human leukocyte antigen class II 
IA: Immune Activation 
IDV: Indinavir 
IFN: Interferon 
IL: Interleukin 
INR: Immunological Non-responder 
INSTI: Integrase strand transfer inhibitors 
IR: Immunological responder 
ISG: Interferon-stimulated genes 
 12 
 
LPAC: Lamina propria aggregate culture 
LPS: Lipopolysaccharide 
LPV: Lopinavir 
LRR: Leucine-rich repeat domain 
LTR: Long Terminal Repeat 
MDM: Monocyte-derived-macrophages 
MHC: Major histocompatibility complex  
MT: Microbial Translocation  
MVC: Maraviroc 
NFV: Nelfinavir 
NK: Natural Killer cells 
NLR: NOD-like receptors 
NNRTIs: Non-Nucleoside Reverse Transcriptase Inhibitors 
NOD: Nucleotide binding and oligomerization domain also known as 
NATCH or NBD 
NRTIs: Nucleoside Reverse Transcriptase Inhibitors 
NVP: Nevirapine 
PAMP: Pathogen-associated molecular pattern 
PBMCs: Peripheral Blood Mononuclear Cell 
PBS: Phosphate-Buffered Saline 
PCR: Polymerase chain reaction 
PIs: Protease inhibitors  
PRR: Pattern-recognition receptor 
PYD: Pyrin domain 
RAL: Raltegravir 
RNA: Ribonucleic Acid 
RTE: Recent Thymic Emigrant 
RTV: Ritonavir 
SIV: Simian immunodeficiency virus 
SQV: Saquinavir 
ssRNA: Single-strand ribonucleic acid 
TCR: T-cell Receptor 
TDF: Tenofovir 
TGF: Transforming growth factor also known as tumor growth factor 
Th: T helper cell 
TLR: Toll-like receptor 
TMC125: Etravirine 
TMC278: Rilpivirine 
TNF: Tumor-necrosis factor 
TPV: Tipranavir. 
TREC: T-cell receptor excision circles 
Tregs: Regulatory T Cells 
ZDV: Zidovudine 
 
 13 
 
 
 
 
 
 
Introduction 
 
Introduction 
14 
 
1. HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND 
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 
 
HIV epidemic was first identified in the 1980s. HIV as a new retroviral virus 
was first identified by Fracoise Barré-Sinoussi and Luc Montagnier in 1983 
and later, in 1984, Robert C. Gallo and his colleagues demonstrated that 
HIV was the causative agent of acquired immunodeficiency syndrome 
(AIDS) [1]–[3]. Nowadays the degree of morbidity and mortality caused by 
HIV infection is still enormous despite the availability of quite effective 
antiretroviral drugs. It is estimated that HIV has infected 50 to 60 million 
people, causing death of more than 25 million individuals. 35 million people 
are living with HIV infection, of which 70% live in Africa, and 1-2 million 
people die of the disease every year [4]. 
HIV is able to infect many different immune cells, especially CD4+ T cells, 
leading to their loss. For this reason, HIV infection is characterized by 
dramatic immune suppression associated with opportunistic infections, 
malignant tumors and neurological degeneration. If not treated, HIV 
infection leads to AIDS and ultimately to death. 
 
1.1 HIV-1Virology 
 
1.1.1 HIV Classification 
 
HIV is a retrovirus belonging to viral Retroviridae family and to the genus 
Lentivirus. Two types of HIV have been identified: HIV-1 and HIV-2. HIV-1 
raised from cross-species transmission of a chimpanzee virus to humans 
[5] and it is by far the most common cause of AIDS and new infections 
globally. It is possible to distinguish three groups of HIV-1 based on their 
Introduction 
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genome differences: M, N and O [6]. In 2009 a new HIV-1 sequence was 
isolated from a single individual and analyzed. This newly analyzed 
sequence was more similar to a simian immunodeficiency virus (SIV) found 
in gorillas, than to SIVs found in chimpanzee. The sequence has been 
placed in group P “pending the identification of further human cases” [7]. 
Group M can be divided into 9 subtypes known as clades (A-D, F-H, J and 
K) and they are responsible for most HIV infections [8]. HIV-2 stemmed 
from cross-species transmission of a sooty mangabey virus and its 
genomic structure and antigenicity is different from that of HIV-1 [9], [10], 
[11]. HIV-2 has lower infectivity and causes a form of AIDS with slower 
progression than HIV-1 [12]. HIV-1 is more common in Europe, America 
and Central Africa, while HIV-2 is more frequent in west Africa and in Asia 
[13].  
 
1.1.2 HIV Genome and Structure 
 
HIV-1 genome is composed by two identical copies of single strand RNA 
and is approximately 9.2 kb long. The whole genome is flanked by long 
terminal repeats (LTRs), which regulate viral gene expression, viral 
integration into the host genome and viral replication. In the viral genome, 
there are structural genes like gag, env and pol and regulatory genes like 
tat, rev, vif, nef, vpr and vpu. Gag sequence encodes core structural 
proteins, while the env sequence encodes the envelope glycoproteins 
gp120 and gp41, both required for infection. The pol sequence encodes for 
reverse transcriptase, integrases and other viral enzymes necessary for 
viral replication. Nef is a virion associated protein and its deletion resulted 
in an asymptomatic infection in macques [14], [15]. Vif is “virion infectivity 
factor” and it promotes viral infectivity. Vpu is present only in HIV-1 and 
shares similar functions to nef and env [16] (Figure 1). 
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Figure 1: HIV-1 genome. Each gene is indicated with a different 
colored block. Genes using the same sequences of other genes are 
shown by overlapping blocks. Colored blocks separated by lines 
indicate genes whose coding sequences are separated in the genome 
and require RNA splicing to produce mRNA. Image from [17] . 
 
An HIV particle has a spherical shape and it is about 100 nm. HIV-1 
consists of two identical positive single strands of RNA (ssRNA), which are 
enclosed by an inner capsid of p24 viral proteins, which is, in turn, confined 
by p17 matrix proteins. Core and matrix are surrounded by a phospholipid 
bilayer envelope derived from the host cell membrane that includes also 
viral membrane proteins such as gp120 and gp41. gp120 and gp41 are 
embedded into the envelope in a trimeric form (Figure 2). 
Introduction 
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Figure 2: HIV-1 Structure. HIV-1 vir ion binding to a T cell through the 
CD4 and other chemokine receptors on the target cell surface. Image 
from [18]  
 
1.1.3 HIV Life Cycle 
 
The binding of gp120 subunits to CD4 molecules on the host target cell is 
the first step of HIV infection and it induces a conformational change that 
allows a secondary gp120 subunit to bind to a chemokine coreceptor 
(CCR5 or CXCR4). This latter binding induces, in turn, a conformational 
change in gp41 which allows the exposure of a hydrophobic region, called 
fusion peptide, which inserts into the host cell membrane and allows the 
viral membrane to fuse with the target cell membrane. Once a cell is 
infected, it displays on its cell membrane gp120 and gp41, which may 
mediate cell-cell fusion with an uninfected cell that expresses CD4 and co-
receptors, leading to a new infection (Figure 3) [19]. The most important 
Introduction 
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chemokine co-receptors for HIV are CXCR4 and CCR5. CCR5 is 
expressed on macrophages and activated T-cells, while CXCR4’s 
expression is ubiquitous. HIV variants are described as X4 for CXCR4 and 
R5 for CCR5 binding viruses, those variants who are able to bind both 
chemokine receptors are called R5X4 [17]. After the fusion, the viral 
nucleoprotein core is disrupted and the viral enzymes become active: the 
viral RNA genome is reverse-transcribed into a single stranded DNA copy 
by the reverse transcriptase, which is then replicated to produce double 
stranded DNA. Then, the viral DNA enters the host cell nucleus together 
with the viral integrase. The reverse transcription process is error-prone 
and it leads to extensive diversity of progeny genomes. Once in the host 
cell nucleus, the viral integrase catalyzes the integration of viral DNA into 
the host cell genome. The integrated HIV DNA is called provirus [18], [20], 
[21]. The provirus may remain transcriptionally inactive for months or years, 
which is the reason why HIV infection may be latent for long periods in 
infected individuals. The transcription of the provirus is regulated by the 
LTR sequence upstream of the viral structural genes and by cytokines that 
activate T cells and macrophages. LTRs regions contain polyadenylation 
signal sequences (TATA box promoter sequence) and binding sites for host 
cell transcription factors - such as NF-kB, SP1, NFAT, AP-1 and STAT- 
which are active in activated immune cells. Cytokines such IL-2 and tumor 
necrosis factor (TNF) stimulate HIV gene expression in infected T cells, 
while other cytokines like interleukin (IL) IL-1, IL-3, IL-6, TNF, interferon γ 
(IFN-γ) and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
stimulate HIV gene expression in infected macrophages [22]–[27]. The fact 
that host factors activate HIV replication is very important to the 
pathogenesis of AIDS because the normal response of latently infected T 
cells to a microbe may lead to virus replication and spread. Therefore, 
multiple infections that HIV-infected patients acquire in their life stimulate 
HIV replication and infections of new cells. HIV gene expression may be 
Introduction 
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divided into an early stage, during which regulatory genes are expressed 
and in a late stage, in which structural genes are expressed. Also, the 
mRNAs, which encode for all the different HIV proteins, are derived from a 
single full genome length transcript by alternative splicing. After 
transcription, viral proteins are translated in the host cell cytoplasm. Soon 
after, the assembly of infectious viral particles begins: full-length RNA 
transcripts of the proviral genome are packaged within a nucleoprotein 
complex including gag core proteins and pol encoded enzymes. The 
nucleoprotein complex then buds from the plasma membrane and during 
this process env and host glycoproteins are included in the viral envelope 
(Figure 4). Some host factors expressed in certain cell types, such as 
tetherin protein, may prevent virion release. Another important restriction 
factor is APOBEC3 (Apolipoprotein B mRNA editing enzyme catalytic 
polypeptide like 3), which is able to interfere with viral replication [18]. 
TRIM5α causes premature viral uncoating and proteosomal degradation of 
viral reverse transcriptase in non-human primates [28]. 
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Figure 4: Schematic representation of HIV life cycle.  Image from 
[18]. 
 
1.2 HIV Pathogenesis 
 
HIV can be transmitted from one individual to another by different routes. 
Sexual contact is the most common mode of transmission (horizontal 
transmission), followed by transmission through needle sticks among drug 
abusers. Infection via blood transfusions have happened in the past when 
little was known about transmission modes of HIV, but nowadays routine 
laboratory screenings on blood transfusions have greatly reduced the risk. 
Another mode of transmission is mother-to-child (vertical transmission), 
which accounts for the majority of pediatric cases of AIDS. Nowadays it is 
Introduction 
21 
 
possible to prevent this type of transmission by treating the mother with 
antiretroviral drugs during pregnancy [18].  
 
 
Figure 5: Natural course of HIV infection.  Image from [29] . 
 
Untreated HIV infection is characterized by three different phases: the 
acute phase, the chronic phase and AIDS (Figure 5). The acute phase is 
characterized by acute infection symptoms, even though the infected 
individual may show non- specific symptoms of infection: it is estimated that 
50-70% of individuals with HIV primary infection develop an acute 
mononucleosis-like syndrome [20]. At this stage the host immune system is 
not able to control the infection and therefore viral loads in blood are high. 
Usually, the virus enter the host via mucosal epithelia where it infects 
memory CD4+ T cells in mucosal lymphoid tissues causing a rapid and 
severe depletion of lymphocytes. Dendritic cells in epithelia are also able to 
capture the virus and then migrate into the lymph nodes, where they can 
infect CD4+ T cells by direct cell-cell contact, causing high levels of viremia. 
Introduction 
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Because of high viremia levels, HIV can then spread throughout the body 
and infect helper T cells, macrophages and dendritic cells. At the same 
time, the adaptive immune system mounts humoral and cell-mediated 
immune responses that partially control the infection and the viral spread, 
which are reflected by a drop in viremia 12 weeks after the primary 
infection. During the chronic phase the immune system is somewhat 
competent at managing various infections, even though HIV replication is 
still present in lymph nodes and spleen, but there is nonetheless a steady 
decline of CD4+ T cells. Yet, at this stage there are no clinical manifestation 
of HIV infection and for this reason this phase is considered a latency 
period. As the disease progresses, the host is more susceptible to new 
infections. The immune response to these opportunistic infections, in turn, 
stimulates HIV production. Therefore, as the immune system is attempting 
to cope with new infections, it facilitates also HIV replication and its own 
destruction. When CD4+ T cells level drops below a certain threshold 
(usually 200 cells/mm3) there is the onset of AIDS, which is the final and 
lethal phase of the disease. During this phase the host is unable to cope 
with any new opportunistic infections because the immune system is 
severely depleted and thus patients are affected with new opportunistic 
pathogens, neoplasms, central nervous system degeneration and even 
kidney failure, which lead to death [29], [30]. 
It is important to take into consideration that the progression of the disease 
is highly variable and that some infected individuals are long-term non-
progressors. In addition, advent of highly antiretroviral therapy has greatly 
improved the course of disease and thanks to therapy patients are now 
able to survive for longer periods.  
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2. HIV IMMUNOLOGY 
 
2.1 Immune responses to HIV 
 
The early immune response to HIV infection is similar to the immune 
response to other viruses, however it provides limited protection and it fails 
to eradicate the infection.  
 
2.1.1 Innate Immune Response 
 
The first line of defense against pathogens is provided by the innate 
immune system. The innate immune system is able to identify pathogens 
by pattern recognition receptors (PPR), which are able to recognize 
evolutionary conserved structures known as pathogen-associated 
molecular patterns (PAMPs). The most well characterized PPRs are the 
family of Toll-like receptors (TLRs). Viral infections are detected by TLR9, 
which recognizes DNA, by TLR7, 8 and 3, which are able to recognize 
either single-stranded RNA (ssRNA) or double-stranded RNA (dsRNA). 
When TLRs recognize the viral pathogens a cascade of cytokine production 
begins. At first there is a rapid increase in the levels of many cytokines, 
which is promoted by DCs, infected CD4+ CCR5+ T cells, monocytes, 
macrophages and natural killer (NK) cells. In particular, there is a rapid 
increase of interferon α (IFNα), which is followed by a transient increase in 
IL-15, IL-18, IL-22, IL-10, IFNγ, TNFα, and CXCL10 levels [31]. IFNα 
inhibits HIV replication at different stages of the viral life cycle and through 
mechanisms mediated by the “interferon stimulated genes” (ISG) [32]. An 
expansion of NK cells has been observed during acute HIV-1 infection and 
it is probably due to high levels of pro-inflammatory cytokines secreted by 
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monocytes and DCs, which is then followed by a decrease of NK cells as 
the disease progress. 
 
2.1.2 Cellular Immune Response 
 
Another important aspect of the immune response against HIV is 
characterized by adaptive immune system, which consists of humoral and 
cellular immune responses. T lymphocytes play a central role in the cellular 
immune response and they can be divided into two main clusters: T helper 
(Th) CD4+T cells and cytotoxic CD8+ T cells (CTL). CD4+Th cells can then 
differentiate into different T cells subsets such as Th1, Th2, Regulatory T 
cells (Tregs) and Th17. Th1 cells produce type 1 cytokines such as IFNγ, 
TNFα and IL-2, which are necessary for the proliferation of T cells, 
activation and differentiation of CTLs cells into memory or terminally 
differentiated CTLs. Th2 cells activate the humoral immune response by 
producing IL-4, IL-5 and IL-13. CTLs main function is to detect and 
eliminate virus-infected cells. CTLs recognize viral antigens associated with 
MHC I molecules on cell surface and, once activated, they produce and 
release perforines and granzymes that can directly kill infected cells [33]. 
CTLs may also induce apoptosis of infected cells by the interaction 
between Fas ligand, expressed on CTLs, and Fas receptor expressed on 
infected cells [34]. During HIV infection the first adaptive immune response 
is characterized by the appearance of HIV-specific CD8+ T-cells and it has 
been established that they play a key role in controlling viral replication [35]. 
These CD8+ T cells are usually specific for env and nef, while CD8+ T cells 
for other viral proteins appear later during infection [36]. Cellular immune 
responses are critical in HIV control as demonstrated by observing the viral 
evolution under immune pressure. Indeed, the evolution of the virus 
resulted in viral isolates that are able to escape to CTLs and CD4+ T cells 
because they have lost their original CTL and CD4+ T cells epitopes [37]. 
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Persistent viremia leads to a functional exhaustion of HIV-specific T cells. T 
cell exhaustion is defined as a condition during which T cells lose 
proliferative and cytotoxic abilities and die by apoptosis [38]. This 
phenomenon has been extensively studied in HIV infection and many 
markers of T-cell exhaustion have been identified such as programmed 
death 1 (PD-1), cytotoxic T-Lymphocyte Antigen (CTLA)-4, lymphocyte 
activation gene (LAG)-3, T cell immunoglobulin domain and mucim domain 
(Tim)-3 [38]. Tregs cells function is to maintain peripheral tolerance and 
preventing autoimmune diseases and chronic inflammation by inhibiting 
immune functions. They suppress antigen-specific-T-cell responses and 
control exaggerate immune activation [39]. In HIV infection, Tregs have 
been shown to play different roles because by inhibiting immune 
responses, they help to suppress immune activation thereby slowing 
disease progression. Conversely, they inhibit antiviral immune responses 
contributing to pathogen persistence and disease progression. Tregs levels 
decline with disease progression, while their frequency increases on 
HAART [40]–[43]. A lot of effort has also been put in describing the ratio 
between Tregs and other pro-inflammatory subsets, such as Th17 T cells 
and imbalances in Th17/Tregs ratios have been reported in HIV-infected 
individuals [44]–[46]. Th17 cells produce IL-17 promoting inflammation and 
the clearance of pathogens, especially at mucosal sites [47]. They have 
also been implicated in autoimmunity diseases, indicating how these cells 
can be both protective and harmful. Human Th17 T cells express CCR6, 
CCR5 and α4β7 integrin, which direct homing to mucosal sites. The role of 
Th17 T cells in HIV infection is not yet fully understood and investigations 
on the role of these cells in HIV infection have reached different and 
opposing conclusions. Recently, HIV-specific Th17 T cells have been 
reported, however another report did not support this finding (reviewed in 
[48]). It has been observed that during HIV infection there is a selective 
depletion of Th17 T cells at mucosal tissues, such as the gastro-intestinal 
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(GI)-tract. The loss of these cells at mucosal GI-tract could result in loss of 
the physical and immunological integrity of the mucosal barrier and in 
leakage of natural flora and thus in immune activation, as it will be further 
explained in next chapter. Less is known about the role of peripheral Th17 
T cells during HIV infection. Maek-a-nantawat et al., stimulated peripheral 
blood mononuclear cells (PBMCs) with phorbolmyristate acetate and 
ionomycin and reported that HIV infected individuals had a significant 
increase in Th17 T cells compared to healthy control. Nonetheless, other 
studies have reached different conclusions and the role of peripheral Th17 
T cells during HIV infection is still a matter of debate [49]–[56]. 
 
2.1.3 Humoral Immune Response 
 
Another important arm of the adaptive immune response is characterized 
by the humoral response. Uptake of viral proteins by DCs and the 
subsequent processing into small peptides activate humoral responses. 
DCs present antigen associated with Major Histocompatibility Complex 
(MHC) II molecules to CD4+Th cells, which then stimulate naïve B cells by 
producing specific cytokines. Subsequently, B cells recognize specific 
epitopes by surface antibodies and differentiate into plasma cells that will 
be able to produce IgG, IgA, IgE and into memory B cells.  
Antibody responses to HIV can be detected within 6 to 9 weeks after 
infection and this process is commonly referred to as seroconversion [57]. 
The most immunogenic proteins of HIV are the envelope glycoproteins, as 
high titers of anti-gp120 and anti-gp41 can be detected in HIV-infected 
patients. The early antibodies usually are not neutralizing and are not 
efficient against the infection. Neutralizing antibodies have been found after 
3 months from primary infection however they are not able to cope with the 
evolving virus. Interestingly, broadly neutralizing antibodies have been 
found in patients who have been infected with HIV-1 for a few years. 
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Broadly neutralizing antibodies bind to epitopes that the virus cannot afford 
to mutate as they are necessary for its own survival, like, for example, the 
CD4 binding site of gp140. Interestingly, these broadly neutralizing 
antibodies which are effective in clearing the infection have been selected 
after extensive somatic hypermutation, which implies that naïve B cells bind 
weakly to antigenic epitopes. Many vaccine strategies are based on the 
production of these broadly neutralizing antibodies, even though so far very 
little has been achieved. 
 
2.2 Immune Activation in chronic HIV infection 
 
Immune activation (IA) is defined as a condition characterized by higher 
frequencies of activated T-cells and B-cells, higher rates of lymphocyte 
turnover and higher plasma and serum levels of pro-inflammatory cytokines 
and chemokines. Persistent immune activation is one of the key features of 
HIV infection and it has led HIV infection to be considered also as a chronic 
inflammatory disease. Indeed, immune activation is considered today one 
of the main drivers of CD4+ T cell depletion and progression to AIDS. 
Several markers have been associated with IA during HIV infection such as 
CD38 expression on CD8+ T cells and HLA-DRII expression in T cells. 
Interestingly, high levels of activated CD8+ T cells were shown to be 
associated with AIDS progression. Higher rates of proliferation, defined by 
Ki-67 expression, have also been associated with IA. In addition, increased 
numbers of HLA-DR+, CD38+ CD8+ T cells were linked to a decrease in 
CD4+ T cell counts and AIDS [58]. It has observed that in each patient the 
level of T cell activation tend to stabilize for a period of time after 6 months 
post-acute infection. This period is thus called “set-point”. T cell activation 
at set-point is predictive of the rate at which CD4+ T cells are lost [59]–[61]. 
Persistent IA is associated with inflammation, microbial translocation (MT) 
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and increased levels of plasma coagulation markers, such as β2-
microglobulin (β2M), TNFα, soluble TNF receptor II (TNFRII), soluble IL-2 
receptor and IFNγ, IL-10 and TGF-β1 [62]–[65]. 
Monocyte and macrophage activation has been investigated too. 
Thieblemont N. et al., and Dutertre et al., have investigated monocyte and 
macrophage activation in relation to disease progression and both studies 
indicated higher numbers of pro-inflammatory CD14+CD16+ monocytes in 
viremic and untreated patients [66], [67]. In addition soluble CD14 (sCD14), 
a marker of monocyte activation and indirect marker of microbial 
translocation, is negatively correlated with CD4+ T cell counts in HIV-2 
infected patients [68]. 
 
2.2.1 Mechanisms of Immune Activation and Microbial Translocation 
 
The mechanisms underlying IA in HIV infection are not yet clear, even 
though many have been proposed. Indeed, understanding the molecular 
mechanisms behind chronic IA is not a simple task. There are many 
multiple mechanisms that have been proposed and it is likely that they may 
synergistically contribute to cause IA (Figure 6). Paiardini et al., suggested 
that it is also very likely that the relative contribution of the different 
mechanisms changes in each HIV-infected individual, during the different 
phases of infection and in naïve or HAART-treated patients [48]. 
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Figure 6: Mechanisms of Immune Activation during HIV infection.  
HIV replication, immune response to reactivated pathogens, microbial 
translocation, increased production of pro-inflammatory cytokines, 
increased homeostatic proliferation and altered balance of CD4+ T cell 
subsets may all contr ibute to immune activation. Image from [48]. 
 
One of the proposed mechanisms of IA is the innate and adaptive immune 
response against HIV. As mentioned before, HIV replicates in active 
immune cells and therefore it promotes T cell activation. Despite this, 
several evidences indicate that high viremia is neither sufficient nor 
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necessary to induce pathological IA levels. Frequency of activated T cells is 
higher than the one of HIV-infected CD4+ T cells and other cell types show 
increased levels of activation [69]–[74]. In addition, even in patients treated 
with HAART, immune activation is still higher compared to healthy 
individuals [75], [76]. HIV proteins have been proposed to be involved in IA 
[77] as well as opportunistic infections, especially in late phase. It has been 
clinically observed that in HIV-infected patients latent viruses such as 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivate more 
frequently than in healthy controls due to CD4+ T cell loss and the 
consequent inability to mount a proper immune response. CMV reactivation 
has been found to promote immune activation and inflammation [78], [79].  
Another important aspect involved in persistent immune activation is the 
loss of mucosal integrity of the GI-tract and the consequent microbial 
translocation (Figure 7). It has been established that during the acute 
infection many CD4+ CCR5+ T cells are lost in the GI-tract [80]–[82]. The 
massive loss of CD4+ T cells in this area compromises the integrity of the 
mucosal intestinal barrier leading to microbial translocation. Microbial 
translocation implies the translocation of microbial and fungal products 
(peptidoglycan, lipoteichoic acid, LPS, flagellin) from the intestinal lumen to 
the system circulation [83], [84]. These microbial products would then be 
able to stimulate many different TLRs and induce the production of many 
pro-inflammatory cytokines such TNFα, IL-6, IL-1β and type I interferons, 
which would, in turn, contribute to persistent immune activation in HIV 
infection [64], [85], [86]. Despite these evidences, the relative contribution 
of microbial translocation to IA is not yet fully elucidated and is still a matter 
of discussion. Indeed, immune activation has been observed also in 
absence of increased levels of LPS in plasma [87]. As mentioned before, in 
SIV/HIV infection, intestinal Th17 T cells loss compromises the physical 
and immunological mucosal intestinal barrier. For these reasons the loss of 
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these cells has been proposed as one of the main causes of microbial 
translocation [52], [88]–[90]. 
 
 
 
Figure 7: Microbial Translocation in HIV-infected individuals. In 
healthy subjects the mucosal barrier is preserved thus limiting the 
leakage of bacteria into blood. However in HIV-infected patients, the 
mucosal barrier is damaged due to CD4+ T cell loss causing bacterial 
products leakage in blood stream and IA. Image modified from [91]. 
 
Central memory (CM) CD4+ T cells (CD62L+ and CCR7+) reside in the 
lymph nodes and, while not displaying strong effector functions, they are 
able to proliferate in response to antigenic re-stimulation and are thus 
important in maintaining CD4+ T cells homeostasis. These cells represent 
the largest reservoir of HIV-1 infected CD4+ T cells [81], [92]. CM CD4+ T 
cells have been proposed to be important in the establishment of chronic 
immune activation. Indeed, depletion of CM CD4+ T cell during infection 
may lead to T-cell homeostatic proliferation and, considering that they 
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harbor high levels of infection and that they reside in lymph nodes, they 
could also contribute to higher viral replication and thus immune activation.  
Many studies have also focused on Tregs as they are deeply perturbed in 
HIV/SIV infection. Tregs are usually defined as CD25 high, CD127 low and 
Fork head Box P3 protein (FoxP3)+and their main function is to lessen the 
effector activity of other immune cells by secreting anti-inflammatory 
cytokines such as IL-10 and TGF-β. Data on Tregs during HIV infection are 
somehow conflicting, even though there have been clear evidences that 
Tregs percentage in blood is increased, while their absolute counts are 
reduced [93]. Interestingly, the ratio of Th17 to Tregs cells is decreased in 
blood and GI-tract of HIV-infected patients and positively correlates with 
increased plasma markers of microbial translocation [94]. How Tregs could 
impact chronic immune activation is not yet clear. On one hand, these cells 
are considered harmful because they are able to suppress HIV-specific 
immune response, on the other they are considered beneficial as they 
could reduce inflammation. Interestingly, it has been demonstrated that 
depletion of Tregs correlates with CD4+ and CD8+ T cell activation in HIV 
infection [44], [95], [96]. 
Type I interferon have also been proposed as inflammatory mediators that 
could contribute to IA. They are released by innate immune cells upon 
recognition of HIV products by PRRs. Physiologically, type I interferon 
induces the expression of hundreds of genes known as interferon-
stimulated genes (ISGs), which restrict intracellular pathogens. In the 
context of HIV infection the persistent expression of ISGs could actually be 
harmful by inducing the chronic production of pro-inflammatory chemokines 
and thus immune activation [97]. On the other hand, a large clinical study in 
which IFNα was administered for 12 weeks to HIV infected individuals not 
receiving HAART revealed that IFNα was well tolerated, increased some 
immune activation markers on CD8+ T cells, reduced plasma viral load and 
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no signs of AIDS progression were observed [98], [99], confirming previous 
data by Lane H.C. and colleagues [100], [101]. 
 
2.2.2 Immune Activation and HIV Pathogenesis 
 
Even if the causes of IA have not yet been fully elucidated, it has become 
clear that it plays a critical role in the pathogenesis of HIV infection.  
Considering that HIV replicates in activated immune cells, persistent 
immune activation may provide available targets for HIV virus replication. 
This situation may trigger a vicious cycle in which new rounds of infections 
stimulate immune activation, which is able in turn to stimulate new 
infections leading to CD4+ T cell loss. In addition, CD4+ T cell loss may 
trigger a homeostatic response able to induce activation and proliferation of 
immune cells in order to replenish the lost cells. This situation, while trying 
to preserve the immune system, also provides new substrates for HIV 
replication. It should also be mentioned that persistent IA deregulates the 
architecture of immune tissues, such as bone marrow, thymus and lymph 
nodes. 
It has also been observed that IA may inhibit the normal functions of B 
cells, NK cells, DCs and monocytes leading to less viral control and even 
more immune activation [48], [102]. 
Persistent activation of monocytes and increased plasma levels of pro-
inflammatory cytokines (IL-6, sCD14, D-dimer) may induce damages in the 
vasculature which result in cardiovascular diseases [103], [104]. 
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3. HIGHLY ACTIVE ANTIRETROVIRAL THERAPY 
(HAART) AND IMMUNE RECONSTITUTION 
 
Nowadays management of HIV infection includes the use of many different 
antiretroviral drugs, which are able to inhibit different steps of HIV 
replication cycle. The first drug to be approved for HIV infection treatment 
was zidovudine (AZT) in 1987 by the US Federal and Drug Administration 
and it was soon followed by the introduction of new antiviral drugs during 
the next decade. Major breakthroughs in the treatment of HIV infection 
using antiretroviral therapies began in 1995-1996 with the introduction of 3-
drug therapy into clinical practice and the so called “combinational 
antiretroviral therapy”, which lead to 80% decline in rates of AIDS, death 
and hospitalization of HIV-infected patients. ART transformed HIV infection 
from being a fatal condition leading to progressive immunodeficiency and 
ultimately to premature death into a chronic and non-fatal condition [105]. 
Antiretroviral drugs can be classified according to the viral life-cycle phase 
that they inhibit. In particular, there are 6 different classes: 
 
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs): NNRTIs are 
able to bind to and block HIV reverse transcriptase, thus preventing HIV 
from replicating. They interfere with the reverse transcriptase activity by 
blocking the hydrophobic pocket of the p66 subunit, which in turn leads 
to a conformational change that alters the catalytic site of the reverse 
transcription enzyme. Commercial drugs are Efavirenz (EFV) and 
Nevirapine (NVP), which are also considered first generation NNRTIs. 
Etravirine (TMC125) and Rilpivirine (TMC278) are considered second 
generation NNRTIs. HIV-2 is naturally resistant to this type of drugs.  
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- Nucleotide reverse transcriptase inhibitors (NRTIs): NRTIs are able to 
block HIV reverse transcriptase, however their mechanism of action is 
different from that of NNRTIs. NRTIs act as competitive inhibitors by 
blocking nucleosides addition to the DNA chain during the reverse 
transcription of HIV. Some currently used NRTIs are Abacavir (ABC), 
Emtricitabine (FTC), Lamivudine (3TC), Stavudina (d4T), Tenofovir 
(TDF) and Zidovudine (ZDV). 
 
- Protease inhibitors (PIs): PIs are able to block HIV protease enzyme 
preventing new immature HIV virions from becoming infective viruses. 
Drugs belonging to this class are Atazanavir (AZT), Darunavir (DRV), 
Fosamprenavir (FPV), Indinavir (IDV), Lopinavir (LPV), Nelfinavir 
(NFV), Ritonavir (RTV), Saquinavir (SQV) and Tipranavir (TPV). 
 
- Fusion Inhibitors (FIs): FIs block HIV fusion with the target cell. They 
work in competition with gp41, blocking entry process of the virus into 
the host cell. Enfuvirtide (ENF) is a FI. 
 
- CCR5 antagonists: They are able to block HIV entry into host cells by 
binding to CCR5 receptor. Maraviroc (MVC) belongs to this class. When 
administering this drug, some caution should be used as it may be 
possible a shift in tropism which allows HIV to target other co-receptors 
such as CXCR4. 
 
- Integrase strand transfer inhibitors (INSTI): These drugs work by 
blocking HIV integrase from incorporating HIV DNA into the host cell’s 
genome. Drugs belonging to this class are Raltegravir (RAL) and 
Elvitegravir.  
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Nowadays the therapeutic approach to treat HIV infection is based on a 
combined therapy in which drugs belonging to different classes are 
administered to achieve a synergistic effect. This type of therapy is called 
Highly Active Antiretroviral Therapy (HAART). A standard antiretroviral 
regimen usually consists of two NRTIs plus one NNRTIs or a combination 
of two NRTIs plus one PI. Mono-therapy has been shown to be 
unsuccessful: the use of a single inhibitor allows the emergence of new 
mutant viruses which are resistant to the drug due to both the extreme HIV 
genetic variability and the selective pressure applied by the drug itself. The 
combination therapy allows a drastic and stable viral load suppression and 
a rapidly increase in CD4+ T cell counts and delays in time the emergence 
of new mutant viruses. In addition, current guidelines suggest testing 
genotyping drug resistance at the time of HIV diagnosis in order to choose 
the right combination of antiretroviral drugs. In general, HAART efficacy is 
achieved in 4-6 months after initiation with suppression of viral replication 
(< 50 copies/ml) and an increase of 100-150 cells/mm3/year of CD4+ T cell 
count [106], [107], [108]. It needs to be mentioned that the success of 
antiretroviral therapy greatly depends on the patient’s adherence to the 
treatment regimen and one of the most common causes of suboptimal 
adherence is poor tolerability of ART treatment. In fact, adverse events 
have been associated with antiviral drugs and they can be classified as 
being short-term (such as anemia, dizziness, diarrhea, fatigue, nausea and 
vomiting, headaches, pain and nerve problems as well as coetaneous 
rashes) and long-term. Some of the most common long-term effects are 
lipodystrophy, insulin resistance which may lead to diabetes, lipid 
abnormalities characterized by increases in cholesterol and triglycerides, 
decrease in bone density and lactic acidosis. In order to avoid long-term 
complications of HAART, it is possible to change the drug regimen. 
Recently, the medical and scientific community has also looked into the 
possibility of suspending HAART regimen for short periods in order to 
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reduce toxic effects of long-term therapy and to improve patient’s 
compliance. One of these largest studies was the SMART trial funded by 
the National Institute of Health. However the SMART study demonstrated 
that the benefits of continuous antiretroviral therapy outweighed the risks of 
long-term side effects. Another important aspect of HAART therapy is when 
it should be started. Current guidelines suggest starting HAART upon HIV 
diagnosis, especially if CD4 count is <350 cells/mm3. Data from two large, 
randomized controlled clinical trials ART-START (Strategic Timing of 
Antiretroviral Therapy) and TEMPRANO demonstrated a 50% reduction in 
both morbidity and mortality among HIV-infected patients with CD4 counts 
>500 cells/mm3 randomized to receive ART immediately versus delaying 
initiation of therapy [109]–[114]. Interestingly, more recently, there have 
been many evidences that HAART may prevent HIV infection and 
transmission. Indeed, two studies demonstrated that lower plasma HIV 
RNA levels are associated with a decrease in the virus concentration in 
genital secretions and studies of HIV-serodiscordant heterosexual couples 
showed that lower HIV plasma levels are associated with lower 
transmission rates [115]–[117]. 
 
3.1 Immune reconstitution in HAART 
 
HAART reconstitutes CD4+ T cell counts in a tri-phasic process: the first 
phase is characterized by an initial high increase in CD4+ T cells due to 
reduced apoptosis and redistribution of memory CD4+ T cells from lymphoid 
tissues to the blood compartment; the second phase is characterized by a 
slower continuous increase in part caused by generation of naïve CD4+ T 
cells, while the third phase is characterized by a normalization of naïve and 
memory CD4+ T cell compartments (Figure 8). Moreover, upon HAART 
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initiation there is a decrease of previously expanded HIV-specific T cells 
and a re-expansion of previously depleted pathogen-specific T cells [118]. 
More specifically, during the first 3 months of therapy there is a rapid 
reduction in viral load, which is accompanied by an increase of CD4+ T cells 
(+200 cells mm−3 year−1), especially of peripheral memory CD4+ T cells. 
There is also a reduction of circulating inflammatory cytokines and 
chemokines such as TNF-α, IL-6 and MCP-1, which is accompanied by a 
decrease in activation markers on CD4+ and CD8+ T cells and in activation-
induced cell death [119].  
 
 
 
Figure 8: Dynamics of CD4+ T Cell reconstitution during HAART. In 
the first months after HAART init iation, the inhibit ion of virus 
replication leads to a rapid increase in CD4+T cells(+200 cells mm−3 
year−1).Subsequently there is another increase (+80 cells mm−3 year−1) 
due to regeneration of naïve CD4+ T cells. This is then followed by 
another slope (+20 cells mm−3 year−1) a normalization of naïve and 
memory CD4+ T cell compartments and cellular activation parameters. 
Image from [118] and [120] . 
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The initial reconstitution of CD4+ T cells during the first phase is a 
consequence of a redistribution of memory CD4+ T cells from the lymphoid 
tissues towards the blood: immunophenotype analysis showed an up-
regulation of CD45RO expression (marker of memory T cells) and a down-
regulation of adhesion molecules like VCAM-1, ICAM-1, CCR7 and CD62L, 
which are necessary to maintain CD4+ T cells into secondary lymphoid 
organs. Therefore the down-regulation of these adhesion molecules 
suggests that CD4+ T cells are released from lymphoid organs into the 
periphery. During the first 3 months of HAART there is also an increase of 
CD8+ T cells, NK cells and B cells in the peripheral blood, which seems to 
depend on cell redistribution [121], [122] (Figure 9). During this phase there 
is also a decrease of previously expanded HIV-specific T cells and a re-
expansion of previously depleted pathogen-specific T cells recovered from 
pre-existing residual memory T cells [123], [118]. This recovery is strictly 
dependent on the control of HIV replication and it seems to be independent 
of CD4+ T cell count and disease stage at HAART initiation [124], [125]. 
The second phase occurs after one year of HAART, when there is an 
increase (+80 cells mm−3 year−1 slope, in Figure 1) in CD4+ T cells due to 
the regeneration of naïve CD4+ T cells [123], which is fundamental in 
restoring the diversity of CD4+ T cell receptor (TCR) repertoire [126]. It has 
been demonstrated that the second phase of HAART immune recovery 
depends on the magnitude of viral replication control and it is not correlated 
on CD4+ T cell depletion before treatment [127], [128]. After the second 
phase, there is a normalization of naïve and memory CD4+ T cell 
compartments and cellular activation parameters (+20 cells mm−3 
year−1slope, in Figure 8). 
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Figure 9: Recovery of pathogen and HIV-specific T cells by HAART. 
Broken yellow line: reconstitution of memory T cells specific for 
opportunistic pathogens; broken orange line: burden of pathogens, 
which decreases upon restoration of specif ic memory T cells (broken 
yellow line). HIV-specif ic effector and effector memory CD4+ and 
CD8+T cells (red line) decreases upon reduction of plasma HIV viral 
load (turquoise line). Pink l ine: HIV-specific central memory CD4+ T 
cells: their restoration is possible thanks to the persistence of some 
HIV antigens from HIV reservoirs (blue line) and IL-7 dependent T cell 
homeostasis. Image from [118]. 
 
The increase of naïve CD4+ T cell during the second phase depends on 
restoration of thymic production on naïve cells and not to conversion of 
memory CD45RO+ CD4+ T cells. This observation was demonstrated by 
analyzing the TCR rearrangement excision circles (TREC). TRECs are 
episomal DNA fragments that are excised during TCR gene rearrangement 
in the maturing T cells in the thymus: Naïve T cells with higher levels of 
TRECs were observed after HAART, reflecting the output of recent thymic 
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emigrants [129]. It should be noted that that the high concentration of 
TRECs content could be due IL-7 level normalization. Indeed, before 
HAART treatment, IL-7 levels are high due to CD4+ T cells homeostatic 
proliferation to compensate the cell loss; after HAART, IL-7 levels tend to 
normalize, thus reducing the homeostatic proliferation and enriching the 
CD4 TRECs content without increasing thymic output [130]. Nonetheless, 
the rise in CD4+ T cells depends also on the homeostatic proliferation of the 
residual CD4+ T cells and on the extension of CD4+ T cells half life.  
The mechanisms of immune reconstitution are not qualitatively 
comparables. Healthy T cells are able to recognize many different 
pathogens because of their repertoire, which allows them to recognize 
many different antigens. During HIV infection there is a reduction in this 
repertoire due to CD4+ T cells loss. If the increase in CD4 counts stem from 
de novo T cell production there will be a restoration of this repertoire, 
however if this increase stems from homeostatic proliferation or extension 
of CD4+ T cells half life, the T cell repertoire will remain truncated.  
 
3.2 Immune Failure in HAART: Immunological Non-
Responders (INRs) 
 
Achieving a good virological and immunological response is important 
during HAART. A good virological response is reached when HIV 
replication is inhibited and can be monitored by evaluating plasma HIV viral 
loads in the affected individual. It is also important to achieve a good 
immunological response because it reduces morbidity and mortality among 
HIV-infected individuals [131]–[135]. A good immunological response is 
reached when CD4+ T cell counts are normalized and generally above 500 
cells/µl because most HIV-infected individuals with these levels of immune 
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reconstitution have morbidity and mortality rates close to uninfected 
individuals [136]. 
Nevertheless, 15-30% of HAART treated patients fail to restore CD4+ T cell 
counts despite fully suppressed viral replication [119], [123], [137]. These 
individuals are referred to as “Immunological Non Responders” (INRs). 
There is a certain lack of consensus regarding the definition of INR. 
Usually, INRs are defined as having CD4+ T cell counts <350 cells/µl, 
however some studies consider INRs only those with CD4+ T cell counts 
<200 cells/µl and treatment duration necessary to define patients as INR is 
variable. Some other groups have defined INRs by the percentages of 
CD4+ T cell increase, commonly <20% increase from baseline [124], [138]–
[140]. Recent data showed that CD4+ T cell counts <350 cells/µl are 
associated with the risk of non-AIDS-clinical events, therefore nowadays 
Guidelines of the Department of Health and Human Services define 
immunological failure as the lack of increase in the CD4+ T cell count to 
more than 350-500 cells/µl after 4-7 years of effective HAART [141], [142]. 
There is a clinical concern regarding the long-term risks of subclinical 
immunodeficiency and many studies have tried to elucidate the 
immunological dynamics that may cause this immune failure. Many factors 
have been associated with immunological failures, such as older age [143], 
probably due to a decrease of thymic function and other functional 
impairments [131], [134], [144]–[146], [147], longer duration of HIV infection 
prior to HAART initiation, co-infections with viral hepatitis viruses and lower 
nadir CD4+ T cell counts [131], [144], [145], [148]–[152]. None of these 
factors provide a comprehensive explanation for the immune failure in 
INRs. For this reason many studies have tried to elucidate the mechanisms 
that lead to immunological failure (Figure 10). 
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Figure 10: Dynamics of Immune Failure during HAART. INRs have 
reduced bone marrow progenitors production and thymic output, which 
leads to a decreased pool of naïve T cells. INRs show increased 
homeostatic proliferation. In the gut, CD4+ T cell depletion leads to 
microbial translocation, which contr ibutes to IA. Lymphoid t issue is 
damaged impair ing de novo T cell production. Reactivation of latent 
viruses and co-infections may contr ibute to IA. Residual HIV replication 
may play a role in immunological failure too. Image from [153]. 
 
Before analyzing the immunological dynamics at the basis of immune 
failure, we should consider that the CD4+ T cell count in a given individual 
at any time is the result of production, destruction and traffic between 
lymphatic tissues and blood. Therefore INRs may have alterations either in 
the production or destruction of CD4+ T cells leading respectively to a 
reduction of output or to an increased turnover. Furthermore, the 
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distribution of CD4+ T cells between blood and lymphatic tissues may be 
different in INRs compared to immunological responders (IR) individuals.  
 
3.2.1 Failures in the production of CD4+ T Cells in INRs 
 
Thymus function has been demonstrated to be particularly important in 
immune restoration. CD4+ T cells generate by proliferation from already 
existing CD4+ T cells or they are produced de novo in the thymus. Only the 
CD4+ T cells produced in thymus display a full immunological repertoire 
because the genesis of TCR takes place only in this organ [154], [155]. 
Interestingly, it has been reported that HIV-infected patients with larger 
thymuses have a better immune recovery and broader immunological 
repertoire than patients with a small thymus [155], [156]. Different studies 
have been conducted in order to assess thymic function in HIV-infected 
individuals. Some groups have visualized thymic tissue in HIV-infected 
adults on computed tomography (TC) and the size of the thymus has been 
positively associated with both naïve and total CD4+ T cell counts [155]–
[158], others have assessed thymic function by looking at TRECs, recent 
thymic emigrants (RTEs) and naïve CD4+ T cells. In fact, during the 
maturation process, T cells migrate from the thymus to the periphery and 
during this process they are classified as RTEs. They will then mature into 
naïve T cells. However, it has to be taken into consideration that thymic 
output is reduced with age and therefore, in such conditions, naïve cells are 
going to be increasingly generated by proliferation [159]. Many studies 
have demonstrated that the naïve T cell compartments in INRs seems to be 
more perturbed than the one in IRs and that INRs have a hypofunctional 
thymus [139], [160]. In particular, it has been suggested an altered 
thymopoiesis in INRs, which is supported by the finding of decreased levels 
of T cells expressing CD28 and by higher percentages of peripheral 
proliferation marker Ki-67 observed in INRs [161]. Immunological failure 
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has been also associated to lower thymopoietin levels in INRs [138], [162]–
[164]. 
Impairments in bone marrow progenitor cell growth have been described in 
HIV-infected patients [165]–[167] and it is known that many hematopoietic 
progenitor cells (HPCs) express receptors CD4, CCR5 and CXCR4 and 
that could be therefore susceptible to HIV infection [168], [169]. Recent 
observations have hypothesized that immune failure in INRs could be in 
part explained by impaired bone marrow functionality [160], [170]–[173].  
Another important role in T cell homeostasis is played by cytokines. As 
mentioned in the previous paragraph IL-7/IL-7R pathway is important in 
maintaining a correct T cell balance and HIV-infected individuals show 
higher serum levels of IL-7 and reduced levels of IL7R compared to healthy 
controls (HC) [174]. This pathway has been studied also in INRs and one 
study found that INRs’ reduction of naïve CD4+ T cells was associated with 
a reduced expression of IL-7R and increased levels of IL-7 [138] and other 
studies confirmed higher levels of IL-7 in INRs compared to IRs [160], 
[161], [175]. Higher levels of IL-7 in INRs are somewhat considered to be 
expected given the physiological role of IL-7 (promoting CD4+ T cell 
production) and it may suggest that immunological signals are not impaired 
in INRs and that the lack of immune recovery might be attributed to the 
source of CD4+ T cells.  
Others cytokines have been found to be altered in HIV-infected individuals: 
IL-2 and IL-15 levels seem to be down-regulated [176], [177]. Production of 
IL-2 has been shown to be decreased in INRs compared to IRs [139], 
which is highly interesting considering IL-2 role in T cell proliferation.  
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3.2.2 Excessive destruction of CD4+ T Cells in INRs 
 
Immunological failure in INRs may also depend on excessive 
CD4+Tcellsdestruction. One of the drivers of excessive destruction may be 
immune activation (IA). IA, as mentioned previously, is a key feature of HIV 
infection and HIV-infected patients, even on therapy, show elevated levels 
of activation markers [178], [179]. Hazenberg and colleagues proposed that 
IA may lead to CD4+ T cell depletion by eroding the naïve T cell pool in 
untreated HIV infection [180]. Interestingly, many researchers have shown 
that INRs have higher levels of IA compared to HIV-infected individuals 
even though there are still no clear evidences that associate IA to 
excessive destruction of CD4+ T-cells [138], [139], [161], [164], [181], [182]. 
Mavigner et al., have reported that increased residual viremia can be 
detected in INRs and it seemed to be linked to increased IA in these 
patients [183]. INRs have also shown to have higher levels of proviral DNA 
in different subsets of CD4+ T cells even during viral suppression and this 
condition could lead to increased CD4+T cell activation and loss [164], 
[184], [185]. Other studies reported higher frequencies of CXCR4 virus in 
INR: this is an interesting observation as X4 viruses appear later during HIV 
infection and they have been associated with increased thymic destruction, 
suggesting that X4 viruses may contribute to the depletion of naïve CD4+ T 
cells [186]. 
Recently, Marchetti et al., reported a consisted trend of high levels of 
plasma LPS in INRs, compared to HIV-infected individuals with full 
immunological recovery. Higher levels of plasma LPS in INRs are also 
correlated with the proportion of activated Ki67+, CD4+ and CD8+ T cells 
[187]. This observation is of particular interest because recent works - in 
particular by Brenchley et al., associated increased microbial translocation 
products from the gastrointestinal lumen, such as LPS, to a continuous 
trigger of immune activation in HIV-infected patients [83], [91], [188]. 
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Indeed, according to Marchetti et al., microbial translocation may trigger 
continuous peripheral CD4+ T cell activation, which in turn may lead to an 
inefficient immunological recovery in INR patients [91]. Despite these 
evidences, the role of microbial translocation in cART-treated individuals is 
still not clear [189]. 
A role for increased destruction of CD4+ T cells may also depend on 
increased senescence and apoptosis of immune cells in HIV infection. It 
has been demonstrated that HIV infected patients have shorter telomere 
length and irregular telomerase activity, which is associated with cellular 
senescence and apoptosis [190], [191]. Many reports have shown that in 
INRs there are elevated levels of apoptosis of CD4+ T cells [192]–[196]. 
Activation-associated T cell molecule programmed death-1 (PD-1) is a 
negative regulator of T cells and is selectively up-regulated in exhausted T 
cells during chronic viral infections [197]. Interestingly, Nakanjako et al., 
and Grabmeier-Pfisterhammer et al., have shown elevated levels of PD-1 in 
INRs compared to IRs [181], [198]. In our lab we have observed the same 
phenomenon too, suggesting that in INRs there is a certain degree of 
immune exhaustion [196]. 
In more recent studies, scientific focus has been on the discovery of new T 
cell subsets with pro- and anti-inflammatory properties. In particular, as 
mentioned previously, two subsets of CD4+ T cells have been gained 
attention: Th17 cells with pro-inflammatory properties and regulatory T cells 
(Tregs) with anti-inflammatory properties. It has been shown that Tregs 
levels decline with disease progression, while their frequency increases on 
HAART [40]–[43]. However, in a prospective study Tregs were measured in 
HIV-infected patients before and after HAART and in healthy controls. In 
this study, Tregs levels were found to be higher in patients than in controls 
[41]. Other studies have reported increased fractions of Tregs in INR 
compared with immunological responders, in particular, activated Tregs 
appear to be more frequent, while resting Tregs are reduced [196], [199]–
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[202]. Thus it is still unclear whether Tregs are beneficial or harmful by 
down-regulating HIV-specific responses and their role in immune 
reconstitution is still debated. 
Th17 T-cells undergo a rapid depletion during infection and a dysregulated 
ratio of Th17 cells and Tregs have been associated with high IA, microbial 
translocation and disease progression in HIV infection [94], [203]. Recently, 
Gaardbo et al. reported disturbances in the Tregs and Th17 cell 
compartments in INRs, suggesting a potential role of these two subsets on 
immune reconstitution [200]. In another recent report, Girard and 
colleagues have found increased frequency of peripheral β7+ Th17 and 
Treg cells in INRs compared to IRs and healthy controls probably to 
replenish the lost cells in the gut. However, once in the gut these CCR6+β7+ 
Th17 are more sensitive to infection than Tregs and could disturb the 
mucosal Th17/Tregs ratio [204]. 
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4. INFLAMMASOMES AND HIV PATHOGENESIS 
 
4.1 Inflammasomes 
 
Inflammasomes were first discovered by Tschopp and colleagues in 2002. 
They are multimeric protein complexes that are able to recognize many 
different stimuli. They are a key component of the innate immune system 
and are fundamental in order to eliminate pathogens and host infected 
cells. Many different types of inflammasomes have been discovered since 
their first description, however they are characterized by a similar core 
structure. It usually consists of a unique patter-recognition receptor (PRR), 
which is activated in response to pathogen-associated molecular patterns 
(PAMPs) or other endogenous danger signals in the cytosol. PRR 
activation leads to oligomerization and recruitment of an adaptor protein 
known as ASC, which is composed of two death-fold domains: a pyrin 
domain (PYD) and a caspase recruitment domain (CARD). The adaptor 
protein ASC bridges the inflammasome to caspase-1: it binds the PRR 
through its PYD domain and it binds to caspase-1thanks to its CARD 
domain. Caspase-1 is then processed into active protease caspase 1, 
which, in turn, is able to initiate downstream responses by releasing IL-1β 
and IL-18 and by inducing pyroptosis, which is a form of programmed cell 
death characterized by high levels of inflammation [205], [206]. Some PPRs 
have a CARD domain and they are able to recruit caspase-1 without ASC 
protein. Indeed, inflammasome’s oligomerization occurs through homotypic 
PYD-PYD or CARD-CARD interactions [207], [208]. Inflammasomes 
containing PYD domains, such as NLRP3, AIM2 and pyrin, recruit ASC for 
the complete assembly, whereas the ones containing CARD domains, such 
as NLRC4, are able to directly bind caspase-1. All inflammasomes are able 
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to induce pyroptosis however ASC-mediated complex assembly is 
necessary for cytokine processing [209]–[212]. 
Inflammasomes can be distinguished according to their structural features 
by their unique PRR and they are usually grouped into nucleotide-binding 
domain-like receptors (NLRs), absent in melanoma 2-like receptors (AIM) 
and pyrin (Figure 11). Recently “non canonical” inflammasomes have 
reported and they are able to target caspase 11 in mice and caspase 4 or 5 
in humans. Other receptors have been confirmed to promote caspase 1 
activation and they are NLRP6, NLRP7, NLRP12, retinoic acid-inducible 
gene I (RIG-I) and IFNγ-inducible protein 16 (IFI16). 
 
 
 
Figure 11: Structure of canonical inflammasomes NLRP1, NLRP3, 
NLRC4, AIM2 and Pyrin. NBD is also known as NOD and NATCH 
domain. Image from [213]. 
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ASC-dependent NLRP3 and AIM2 activation has been studied extensively 
and it has been demonstrated that it is a process that requires two 
nucleation events. Upon sensing a stimulus inflammasomes are able to 
interact with ASC pyrin domain. This interaction leads to the assembly of 
ASC into a large protein specks (known as “ASC specks”), which consist of 
multimers of ASC dimmers. Thanks to CARD domain, ASC is able to 
cluster pro-caspase-1 so that NLRP3 sensor, ASC adaptor and pro- 
caspase-1 are present at increasing concentrations allowing signal 
amplification. This step allows caspase-1 self cleavage and the formation of 
homotetrameric caspase-1. Caspase-1 is then able to process IL-1β and IL-
18 into their active forms. Activation of inflammasomes is an all-or-none 
phenomenon. It has been observed that inflammasomes activation leads 
also to release of ASC specks, which are phagocytosed by adjacent cells. 
This process seems to drive ASC nucleation and new rounds of 
inflammasome activation [214]. 
It has been demonstrated that exists differences in inflammasome 
expression between cell types. In a mice study, it was observed that splenic 
neutrophils, macrophages, monocytes and conventional dendritic cells had 
high expression levels of NLRP3, whereas lymphoid subsets, eosinophils 
and plasmacytoid dendtric cells had lower levels of NLRP3 expression 
[215]. There have been also reports of NLRP3 expression in ganulocytes 
and in human T and B lymphocytes [216], [217]. 
 
4.1.1 NLR Family 
 
NLR cytosolic receptors are involved in recognition of danger-associated 
molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs). NLRs have a common structure consisting of a C-terminal 
leucine-rich repeat (LRR), a central nucleotide-binding and oligomerization 
domain (NOD, also known as NATCH or NBD) and a N-terminal domain 
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which may contain either a pyrin domain (PYD), which is typical of NLRP 
subfamily, or a caspase recruitment domain (CARD), which is typical of 
NLRC subfamily (Figure 12).  
NOD1, NOD2, NLRC4 and proteins with a related but not yet characterized 
domain (known as X) such as NLRX1 belong to the NLRC subfamily, while 
the NLRP subfamily consists of 14 different proteins. When these receptors 
recognize either DAMPs or PAMPs, they are able to trigger the NF-kB and 
MAP kinase signaling cascade and the formation of inflammasomes. 
NLRP1, NLRP3 and NLRC4 are known to be able to form inflammasomes, 
while for others, such as NLRP6 and NLRP12, it has only been established 
their ability to activate caspase-1 [218]. 
 
 
 
Figure 12: Schematic structure of NLRs subfamilies. Image from 
[219]. 
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4.1.1.1 NLRP1 
 
NLRP1 was the first NLRs to be recognized as being able to form an 
inflammasome complex. Humans have only one NLRP1, which consists of 
a NOD and LRR domains, a pyrin domain, a function to find domain and a 
C-terminal CARD domain. In mice, three different NLRP1 have been 
indentified such NLRP1A, NLRP1B and NLRP1C, with a similar domain 
organization but lacking PYD domain [220]. The specific triggers of NLRP1 
inflammasome activation have not yet been fully understood. It has been 
demonstrated that two of the five mice Nlrp1b alleles are activated by 
anthrax lethal toxin, which comprises a protective antigen and a lethal 
factor. The protective antigen is able to generate pores in the host cell 
membrane, whereas the lethal factor is able to promote the cleavage of 
NLRP1 leading to the activation of inflammasomes. Toxoplasma has been 
shown to be able to induce NLRP1 inflammasome activation [221], [218]. 
Interestingly, it has been shown that mice harboring a mutation in the 
Nlrp1a gene (Q593P) develop a systemic inflammatory disease, which is 
mediated by caspase-1 and IL1β. In addition, these mice have a significant 
loss of hematopoietic progenitor cells suggesting an involvement of 
inflammasome activation and pyroptosis in the altered myelopoiesis. In 
humans NLRP1 mutations have been linked to autoinflammatory disease, 
Addison’s disease, rheumatoid arthritis, systemic sclerosis and Crohn’s 
disease [222]. 
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4.1.1.2 NLRP3: canonical and non canonical inflammasome 
 
NLRP3 is the most well characterized inflammasome as it has been 
associated with auto inflammatory conditions [223], [224] and its 
constitutive active form has been linked with many different human 
diseases. NLRP3 can be activated by many different PAMPs and DAMPs, 
such as microbial cell wall components, nucleic acids, toxins, pollutants, 
ATP, serum amyloid A and uric acid crystals [225]. It has been 
demonstrated that NLRP3 basal expression is not sufficient for 
inflammasome activation in resting cells. In most cell types, NLRP3 
requires a priming step and a second activation steps that can be induced 
by different stimuli. Given the diversity of triggers that are able to activate 
NLRP3, it has been assumed that a common upstream signal is required 
for its activation. Many factors have been proposed as upstream signals 
such as, reactive oxygen species (ROS) production, potassium efflux, 
calcium signaling and lysosomal disruption [226]–[233]. The typical 
example of priming stimuli for NLRP3 is the binding of LPS to TLR4. 
Despite this, a unifying mechanism for NLRP3 activation has not yet been 
established and many different activation mechanisms have been 
proposed. It has been suggested that potassium release is associated with 
all NLRP3 activation mechanisms. Recent studies have shown that under 
resting conditions ASC is localized in the mitochondria, cytosol and 
nucleus, while NLRP3 can be found associated with the endoplasmatic 
reticulum [230]. Upon the correct stimulus, the subcellular localization of 
these molecules changes: mitochondria are dynein-transported toward the 
endoplasmatic reticulum allowing ASC to be close to NLRP3. Mitochondrial 
dysfunction are then able to induce microtubule alterations that allow 
NLRP3 to interact with ASC [234]. Interestingly, very recently NLRP3 
activation has been associated with cell-cycle progression. The 
serine/threonine kinase NEK7 is necessary for progression through mitosis 
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and it has been observed that is also able to interact with LRR domain of 
NLRP3 and that this interaction is independent of its kinase activity and 
necessary for NLRP3 inflammasome activation. NEK is able to directly bind 
NLRP3 and to control the oligomerization process [235], [236]. 
 
Recently, it has been shown that inflammasome NLRP3 can also be 
activated thanks to caspase-11 in mice or caspase-4/5 in humans (Figure 
13). This pathway is called the “non canonical inflammasome”. Caspase-11 
has been shown to induce pyroptosis independent of capsase-1 and that it 
is necessary for NLRP3 inflammasome activation, especially in response to 
G ram-negative bacteria [237], [140]. In “Non canonical inflammasome” 
pathway a bacterial toll-like receptor (TLR), such as TLR4, leads to cellular 
priming and consequent up-regulation of NLRP3 and pro-IL1β expression. 
Subsequently, bacterial mRNA activates NLRP3 and LPS stimulates TLR4 
and TRIF (TIR domain-containg protein inducing IFNβ) signaling, which 
leads to secretion of type I IFNs and caspase-11 induction[235], [239].In 
addition, caspase-11 detects intracellular LPS by directly binding it. This is 
facilitated by guanylate-binding proteins (GBPs). The LPS binding results in 
activation of caspases, which then cleaves Gasdermin D to induce 
pyroptosis. This process is able to induce the assembly of NLRP3 and the 
consequent activation of caspase-1 [206], [220], [240]. In humans, active 
caspase-4 can promote the activation the primed NLRP3 inflammasome 
without a canonical NLRP3 activating stimulus [241]. Notably, caspase-11 
and caspase-4/5 are not able to cleave pro-IL1β and pro-IL18, although by 
activating NLRP3 it is still possible to observe cytokine release [238], [242]. 
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Figure 13: Caspase 11-non canonical NLRP3 inflammasome.LPS is 
recognized by TLR4, which then mediates the up-regulation of 
caspase-11 and induction of pyroptosis and NLRP3 inflammasome 
assembly. Caspase-11 is also able to bind intracellular LPS facil itated 
by GBPs proteins. The binding directly activates caspase-11 which 
induces the cleavage of Gasdermin D inducing NLRP3 activation and 
pyroptosis. Image from [213]. 
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4.1.1.3 NLRC4 
 
Salmonella infection, bacterial flagellin and multiple components of the 
bacterial type III secretion system are able to active NLRC4[243], [244]. 
NAIP proteins act as a sensors that recognize the ligands and induce 
NLRC4 activation [244]–[246]. In addition to IL-1β/IL-18 secretion and 
induction of pyroptosis, NLRC4 activation upon Salmonella infection may 
induce actin polymerization response, which prevents bacterial uptake and 
increases ROS production to enhance bacterial intracellular clearing [247]. 
 
4.1.1.4 AIM2 and Pyrin 
 
AIM2 is the main member of the AIM family. It is involved in the immune 
response against many different types of viral and bacterial infections[248], 
[249]. It has been established that Type I IFN signaling is necessary for 
AIM2 activation during bacterial infections only [225], [250]. Pyrin was first 
discovered as an inflammasome in a mouse model of Mediterranean fever 
[222]. AIM2 has been associated with many human diseases such as 
psoriasis, abdominal aortic aneurysm and systemic lupus erythematosus.  
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4.2 Inflammasomes and T Cell Responses 
 
The release of IL-1β and IL-18 by inflammasome activation has many 
different effects on the T helper cell polarization [251], [252] (Figure 14). 
 
 
 
Figure 14: Inflammasome activation and T Cell Responses. IL-18 
stimulates differentiation in Th1 subset in synergy with IL-12, while IL-
1β favours Th17 differentiation. Image from [253]. 
 
It has been demonstrated that IL-1β stimulates T helper differentiation into 
Th17 T cells [254]. It was observed that certain DAMPs, known to activate 
inflammasomes, such as uric acid crystals, were able to promote Th17 
responses in an ASC/caspase-1 dependent manner [255]–[257]. The role 
of inflammasome in Th17 polarization has been extensively studied in 
multiple sclerosis. IL-1β and inflammasomes have been implicated in the 
development of multiple sclerosis, which is driven by Th17 T cells [258]–
[260]. In animal models during Candida albicans infection, it was reported a 
crucial role of caspase-1 and ASC in Th17 polarization [261]. In another 
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study, using Asc-deficient and Nlrp3-deficient mice challenged with 
Schistosoma mansoni, there was a reduction of IL-17 and IFNγ production 
[262]. On the other hand, IL-18 is able to stimulate the differentiation 
towards the Th1 subset by amplifying the production of IFNγ in many 
different infection models of infection [263]. 
 
4.3 Pyroptosis 
 
Inflammasome activation leads to pyroptosis (from the Greek “pyro”, for fire 
and fever, and “ptosis”, which means falling), which is a form of 
programmed cell death dependent on activation of caspase-1 (and also 
caspase-4 and caspase-5). Pyroptosis, contrary to what happens during 
apoptosis, is characterized by plasma-membrane rupture, cell swelling and 
the release of proinflammatory cytokines and intracellular content [264], 
[265].The defining feature of pyroptosis is its dependence on caspase-1. 
Interestingly, caspase-1 is not involved in apoptosis and typical apoptosis 
related caspases, such as caspase-3, caspase-6 and caspase-8 are not 
involved in pyroptosis. Cell membrane rupture during pyroptosis is 
mediated by caspase-1 dependent plasma membrane pores: these pores 
dissipate cellular ionic gradients thus increasing osmotic pressure, water 
influx, cell swelling and finally osmotic lysis and relase of inflammatory 
cytokines and cellular contents [265]. DNA damage has been observed 
during pyroptosis, as well as destruction of the actin cytoskeleton [264], 
[266]–[269]. Pyroptosis has been described in macrophages, monocytes 
and dendritic cells where it contributes to defense against pathogens [270]. 
Contrary to other types of cell death, like necroptosis, in pyroptosis extra 
cytoplasmatic ligands, such as TNF or those that bind to TLRs, do not 
trigger directly pyroptosis but only “prime” the cell to pyroptosis by inducing 
the synthesis of proteins that signal it. The triggering event is the 
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recognition of intracellular pathogen components by PPRs. Caspase-4 and 
Caspase-5 are PPRs themselves and they can be activated by LPS and 
then trigger pyroptosis (non canonical pathway). Caspase-1 is dependent 
on PRRs like NLRs as mentioned in the previous chapter. Despite this, 
clear markers of pyroptosis are still missing. This is mainly due to the fact 
that many molecules involved in cell death are also involved in other 
functions in living cells. Recent studies have suggested that gasdermin-D 
(GSDMD) may be a good marker of pyroptosis. GSDMD is cleaved by 
caspases and it seems to contribute to death induction. Knock-out (KO) 
cells for GSDMD are resistant to the induction of pyroptosis by caspase-11 
(or caspase-4/5 in humans) [206], [240]. 
 
4.4 Inflammasomes, pyroptosis and HIV pathogenesis 
 
Many viruses are able to activate inflammasomes, caspase-1 and the 
production of IL-1β. Therefore, recently the association between 
inflammasomes and HIV has been elucidated by several research teams. 
 
4.4.1 Inflammasomes and HIV-1 
 
One of the first reports about a possible relation between inflammasomes 
and HIV comes from the work of Pontillo A. and colleagues: they reported 
that a 3’ UTR SNP in NLRP3 gene is associated with susceptibility to HIV-1 
infection [271]. The same group observed that HIV-1 was able to induce the 
expression of NLPR3 and IL-1β secretion in alditrithiol-2-inactivated HIV-1 
treated dendritic cells from healthy individuals but not from HIV-infected 
patients, suggesting that NLPR3 inflammasome could play a role in the first 
steps of HIV-1 infection. Dendritic cells from HIV-infected patients, although 
chronically activated, seemed to be unresponsive against pathogens [272], 
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[273]. More recently, it was demonstrated that HIV-1 is able to induce the 
first signal to activate NLRP3 inflammasome in monocyte-derived 
macrophages (MDM). MDMs were primed with LPS or different types of 
HIV-1 (HIV-1VSV-G or HIV-1ΔenvVSV-G) and subsequently treated with 
activators of the second signal for NLRP3 inflammasomes (ATP, nigericin, 
silica, alum and MSU) and then IL-1β production was evaluated. It was 
observed that MDMs primed with either types of HIV-1 were able to induce 
the secretion of IL-1β comparable to the one induced by LPS. In addition, 
they demonstrated that HIV-1 initiates the priming signal for NLRP3 
inflammasome activation through the NF-kB-associated pathway [274]. 
Guo H. et al., investigated how HIV-1 is able to induce IL-1β production and 
they observed that HIV-1 was able to induce the expression of pro-IL-1β via 
TLR8 and that NLRP3 inflammasome was required for IL-1β maturation 
and secretion. In particular, they observed that HIV-1 infection induced 
caspase-1 activation and that NLRP3 inflammasome activation in response 
to HIV-1 is dependent on ROS production and Cathepsin B. Interestingly, 
they also observed that transfection of HIV-1 derived single-stranded RNA 
into THP-1 cells induced caspase-1 activation and IL-1β production, 
indicating that HIV-1 activates NLRP3 inflammasome thanks to its RNA 
[275]. Inflammasome activation has also been studied in the brains of HIV-
infected individuals: in particular, it has been reported that IL-1β, IL-18 and 
capsase-1 were induced in the brains of HIV-infected patients and were 
detected in microglial cells upon HIV-1 infection [276]. More recently, vpr 
HIV protein has been reported to be able to cause caspase-1 cleavage and 
IL-1β release with reduced cell viability dependent on NLRP3 stimulation. It 
was suggested that Vpr may act independently as either or both of the 
inflammasome signals [277]. In addition, it has been demonstrated that 
upon primary HIV/SIV infection, there is a rapid activation of NLRX1 
inflammasome [278]–[280]. The upregulation of NLRX1 is of particular 
interest as it inhibits the antiviral IFN responses, thus promoting HIV-1 
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infection and facilitating HIV-1 reservoirs. Interestingly, Nasi M. et al. 
reported a decreased expression of NLRX1 in ART-treated-HIV infected 
patients, suggesting that antiretroviral therapy may be able to inhibit this 
inflammasome [281]. 
 
4.4.2 Pyroptosis and HIV 
 
Very recently, Doitsh G. et al., demonstrated that the majority of T cells dies 
via pyroptosis during HIV infection [282]. This work has been a huge 
breakthrough in the field because it demonstrated for the first time a key 
role of inflammasomes and pyroptosis in the pathogenesis of HIV. Many 
studies have tried to elucidate how CD4+ T cells are lost during HIV 
infection and many mechanisms have been proposed. At first, it was 
suggested that productively infected and activated T cells were the ones 
dying and that depletion was due to a cytopathic effect of the viral life cycle 
[283]. However, it became clear that the frequency of activated CD4+ T 
cells was very limited and could not explain the massive depletion of this 
cell subset [284]. Therefore, it was suggested that actually most of the 
dying cells were bystander CD4+ T cells in the lymph nodes who were not 
actively infected [70]. Yet, how CD4+ T cells are actually lost during 
infection is still a matter of debate. It was proposed that some host factors, 
such as TNFα, Fas ligand and TRAIL, and viral factors, such as Tat, Vpr 
and Nef, could contribute to cell loss [77], [285]–[287]. Doitsh G. and 
colleagues used an ex vivo human lymphoid aggregate culture (HLAC) 
system using fresh human tonsil or spleen tissues [288] to better 
understand how bystander T cells could die upon HIV infection. They 
observed that infection of HLACs with X4-tropic HIV-1 resulted in almost a 
complete depletion of CD4+ T cells, even if only approximately 5% of these 
CD4+ T cells became productively infected with the virus. Thus, indicating 
that 95% of the dying CD4 T cells were resting CD4+ T cells. Subsequently, 
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they treated these cell cultures with antiviral drugs and discovered that 
bystander CD4+ T cell death was prevented by entry inhibitors and fusion 
inhibitors, but not by NRTIs. Interestingly, the use of NNRTIs blocked CD4+ 
T cell death in HIV-infected HLACs, suggesting that a certain degree of 
viral DNA is required to induce cell death [289], [290]. One of the 
hypotheses was then that cell death observed in these HLACs cultures 
involved abortive viral infection of resting CD4+ T cells. According to this 
model, HIV binds and fuses to bystander CD4+ T cells, however due to their 
resting state, the viral life cycle attenuates during reverse transcription 
giving rise to incomplete cytosolic viral DNA transcripts [290]. These viral 
DNA transcripts are then sensed by IFI16, which is known to induce 
caspase-1 activation [291]. Indeed, treatment of HIV-infected HLACs with 
caspase-1 inhibitor or with shRNA-mediated knockdown of caspase-1 
prevented CD4+ T cells loss. Of note, inhibitor of caspase-3 or shRNA-
mediated knockdown of caspase-3 did not prevent cell loss. Given these 
data, Doitsh G. et al., suggested that death of abortively infected CD4+ T 
cells in HLACs cultures was mediated by pyroptosis. In subsequent studies, 
it was shown that blood cells were highly resistant to pyroptosis and this is 
probably due to their deeper state of cellular rest, which is associated with 
fewer viral DNA and lower expression of innate immune sensors like IFI16. 
It should be noted that when pyroptosis-resistant peripheral blood CD4+ T 
cells were co-coltured with either CD4+ or CD8+ T cells or B cells from 
lymphoid tissues, they readily died by caspase-1 activated pyroptosis 
induced by caspase-1 activation [292]. Galloway and colleagues observed 
that in HLACs models, the mode of viral spread affects cellular death: 
according to them, infection with free HIV-1 particles is unable to trigger 
innate immune recognition and pyroptotic cell death, thus infected CD4+ T 
cells die by apoptosis. On the other hand, cell-to-cell spread of HIV-1 gives 
rise to massive abortive infection, which leads to pyroptosis [293]. These 
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observations are interesting considering that it has always been assumed 
that circulating free virions are the main cause of CD4+ T cell loss [290].  
Doitsh G. and colleagues have also suggested a model in which pyroptosis 
could contribute to sustain chronic inflammation and immune activation in 
HIV infection. In their studies they observed that tissue-derived CD4+ T 
cells are primed to mount inflammatory responses as they produce in high 
quantities pro-IL1β, ASC and NLRP3 inflammasome [282]. In addition, the 
secretion of proinflammatory cellular contents during pyropototic CD4+ T 
cell death may provide a second inflammatory stimulus which could lead to 
the activation of NLRP3 inflammmasome and caspase-1 in surrounding 
CD4+ T cells and thus to new round of pyroptosis, cell death, inflammation 
and immune activation, even when viral replication is suppressed by 
HAART (Figure 15).  
 
 
 
 
 
 
Introduction 
65 
 
 
 
Figure 15: Pyroptosis and HIV pathogenesis in lymphoid tissue. 
Abortive HIV infection of CD4+ T cells leads to cytosolic DNA products 
sensed by IFI16 (1), which leads to pyroptosis and inflammation (2 and 
3). Inflammation promotes the migration of new circulating central 
memory CD4 T cells into the lymph nodes (4) establishing a vicious 
cyle of HIV infection, cell loss and inflammation. Inflammation also 
promotes the recruitment of neutrophils and monocytes in the lymphoid 
organs (5). These cells constitutively express high levels of pro-IL18, 
ASC and NLRP3 inflammasome. The release of pro-inflammatory 
content by pyroptotic cells may activate NLRP3 inflammasome leading 
to new rounds of pyroptosis and cell death even during antiretroviral 
therapy (6). Image from [290]. 
 
Therefore, according to this new interesting model, abortive infections of 
resting CD4+ T cells would lead to HIV DNA sensing by IFI16 and to the 
subsequent activation of caspase-1 and pyroptosis. The release of 
pyroptotic pro-inflammatory content would then activate NLRP3 
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inflammasome, which – in turn – would lead to new rounds of pyroptosis 
and cell death, thus sustaining chronic immune activation in HIV infection. 
Of note, most of the experiments about pyroptosis in HLACs model were 
conducted with X4-tropic HIV isolates, so it still remains to be elucidated if 
R5-tropic HIV viruses induce the same effects. It is established that X4 
isolates may emerge later during infection and have been associated with 
extensive CD4+ T cell loss, however most HIV viruses found in HIV infected 
individuals are actually R5. For this reason, Steele A. and colleagues 
evaluated if pyroptosis occurs in CD4+ T cells after exposure to CCR5-
tropic HIV. They created a model from gut cells called Lamina Propria 
Aggregate Culture (LPAC) and infected them with a R5-tropic HIV isolate. 
They found that the magnitude of cell loss correlated with the productivity of 
HIV infection, however the majority of dying CD4+ T cells was not infected 
and expressed caspase-1, suggesting pyroptosis. Treatment with a 
caspase-1 inhibitor was able to reduce T cell loss, suggesting that 
pyroptosis was one of the major reasons of cell death. 
Given the possible role of microbial translocation in HIV pathogenesis, 
Steele and colleagues performed similar experiments with the addition of 
Escherichia coli. They observed that E. coli enhanced CD4+ T cell depletion 
and caused a shift in the type of cell death from pyroptosis to apoptosis. 
Indeed, in this model, caspase-1 inhibitor was not able to rescue CD4+ T 
cells, however caspase-3 inhibitor was. The authors suggested a model in 
which pyroptosis predominates in the early phases of HIV infection 
contributing to breakdown of gut wall epithelial integrity. Once microbial 
translocation is established, T cells and APCs would be exposed to 
commensal bacteria resulting in enhanced HIV-1 replication. This would 
lead to a shift in the cell death pathway to apoptosis [294]. 
Interestingly, in another work, the expression of IFI16 was significantly 
higher in untreated HIV infected patients. IFI16 expression levels correlated 
positively with viral load and CD38 expression level, thus with immune 
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activation and inversely correlated with CD4+ T cell counts [295].Another 
report suggesting a possible role of caspase-1 in HIV pathogenesis and 
inflammation comes from Song J. and colleagues. They analyzed the 
dynamics of caspase-1 and caspase-3 in the peripheral blood of HIV 
infected untreated patients with CD4+ T cell counts <250 cells/μl (CD4low) 
and in HIV-infected untreated patients with CD4+ T cell counts >450 cells/μl 
(CD4high) within 2 years after primary infection. They observed that 
caspase-1 and caspase-3 plasma levels underwent a rapid increase, 
followed by a decrease after a short time during early infection in the 
CD4high group, probably due to the typical cytokine storm of early HIV 
infection. On the other hand, caspase-1 and caspase-3 levels were not 
increased during acute HIV-1 infection in the CD4low group, which is 
probably due to a weak immune response. However, one year after 
infection, caspase-1 and caspase-3 levels were increased in the CD4low 
group but not in the CD4high group, suggesting that that the rapid disease 
progression of the CD4low group could be associated with cell death later in 
the course of infection [296]. 
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The determinants of immune failure under HAART are incompletely 
understood, even if many factors have been shown to be associated with 
this condition, such as older age, residual HIV replication, impairments of 
CD4+ T cell de novo production and excessive destruction. A suboptimal 
immunological response to HAART may have dramatic clinical 
consequences as INRs are at increased risk of clinical progression to AIDS 
and of non-AIDS related diseases. Indeed, these patients show higher 
levels of immune activation and chronic inflammation compared to other 
HIV-infected individuals under medical treatment. Thus, it is important to 
find new factors associated with immunological failure in order to find new 
possible therapeutic approaches that could help to manage this clinical 
condition and improve HIV-positive subjects’ health. 
Recent discoveries on the role of inflammasomes in immunity and in HIV 
pathogenesis have shed new interesting perspectives on CD4+ T cell loss 
during HIV infection and new possible immunological pathways leading to 
immune activation and chronic inflammation that characterize HIV infection.  
Therefore, the aim of this study is to analyze and evaluate possible 
associations between inflammasomes activation, T cell activation and the 
degree of immune reconstitution in HIV infected HAART-treated patients. 
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1. SAMPLE COLLECTION 
 
1.1 Study Population 
 
39 HIV- infected ART-treated patients were enrolled at the Unit of Infectious 
Diseases, San Gerardo Hospital, Monza, Italy. 22 patients were 
immunological responders (IR) and 17 were immunological non responders 
(INRs). The inclusion criteria were: men and women >18 of age, HIV 
positivity tested with ELISA and confirmed by Western Blot, combined 
antiretroviral therapy, duration of ART > 24 months, plasma HIV-RNA < 50 
cp/mL for at least 12 months, CD4+ T cell count <350/mmc if immunological 
non responder (INR) or >500/mmc if full responder (IR).The exclusion 
criteria were: presence of actual opportunistic AIDS-related diseases, 
chronic inflammatory disorders, immunosuppressive therapy ongoing. 
Written informed consent was obtained from each patient before enrollment 
in accordance with the declaration of Helsinki. 
 
1.2 PBMCs Separation 
 
Peripheral whole blood was collected by venipuncture in Vacutainer tubes 
containing EDTA (ethylenediaminetetraacetic acid) (BD, Rutherford, NJ, 
USA). Samples were centrifuged at 1500 rpm for 10 minutes at room 
temperature to obtain plasma, which was then collected and stored at -
80°C for subsequent analyses. The blood sample was then diluted in 
phosphate buffered saline (PBS) (Euroclone, Milano, Italy) and PBMCs 
were separated by density gradient centrifugation on lymphocyte 
separation medium (Ficoll-Hypaque) (Cedarlane Laboratories Limited) at 
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2300 rpm, without brake, for 25 minutes at room temperature. Ficoll-
Hypaque solution was layered slowly underneath the blood/PBS mixture by 
placing the tip of the pipet containing the Ficoll-Hypaque solution at the 
bottom of the sample tube. 10 ml of Ficoll-Hypaque solution were used for 
35 ml of blood/PBS mixture. PBMCs separation by Ficoll-Hypaque takes 
advantage of the density differences between the mononuclear cells and 
other cellular elements in the blood samples. After centrifugation, the low 
density mononuclear cells and platelets collect on top of the Ficoll-Hypaque 
layer, while the high density red blood cells (RBC) and granulocytes collect 
at the bottom. PBCMs are then collected and washed in PBS and 
centrifuged at 1750 rpm for 10 minutes at room temperature. Cellular 
pellets were dissolved in PBS and cell count and vitality were evaluated. 
 
 
 
Figure 16: PBMCs separation. RBC: red blood cells. Image from 
[297]. 
 
1.2.1 Cell Count 
 
The number and viability of the cell were determined by automated cell 
counter ADAM-MC (Digital Bio, NanoEnTek Inc, Corea). Two sensitive 
fluorescence dye staining solutions, AccuStain Solution T (Propidium 
Iodide/lysis solution) and AccuStain Solution N (Propidium Iodide/PBS) are 
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used to determine cell count. Solution T measures total cell concentration 
by disrupting plasma membrane and nucleus staining. AccuStain Solution 
N stains non-viable cells, thus leaving viable cells completely intact. A 532 
nm optic laser is automatically focused onto the cell solution inserted into a 
disposable microchip and cell analysis is made by a CCD detection 
technology. 
 
1.3 PBMCs Cell Culture and Stimulation 
 
PBMCs were subsequently resuspended in fresh completed medium 
composed of RPMI 1640 (Euroclone, Milano, Italy), 1% L-glutamine 
(Sigma-Aldrich), 1% Pen/strep (Sigma-Aldrich) and 10% Human AB Serum 
(Euroclone, Milano, Italy). For flow cytometry experiments, PBMCs were 
then cultured (1x106 cells/ml) for 18 hours either in complete medium (basal 
condition) or in complete medium with LPS (1 μg/mL) (Sigma-Aldrich) or in 
complete medium with aldrithiol-2 (AT2 treated)-HIV-1BaLvirions (300 
ng/mL) (a kind gift from Julian Bess, Frederick Laboratory for Cancer 
Research, National Institute of Health, Frederick, MD, USA). Treatment 
with aldrithiol-2 suppresses the infectivity of the viral particles, while 
maintaining the conformation and functional integrity of virion surface 
proteins [298]. In cell cultures stimulated with LPS or AT2-treated HIV-
1BaLvirions, anti-CD28 monoclonal antibody (2μg/ml) (R&D Systems) was 
added to facilitate co-stimulation. For cytokine analysis, 1 μg/mL of 
Brefeldin A (Sigma-Aldrich) was added to the cell cultures 6 hours before 
flow cytometry cell staining to block protein secretion. For gene expression 
analyses, PBMCs were cultured as described before, however they were 
stimulated for 3 hours either with LPS or with medium alone (negative 
control) or for 24 hours with AT2 treated-HIV-1BaLvirionsor medium alone 
(negative control). 
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2. FLOW CYTOMETRY ANALYSIS 
 
2.1 Immunophenotypic analysis 
 
Immediately after separation, 0,5x106 PBMCs were stained with 
fluorochrome-labeled monoclonal antibodies for 15 minutes at room 
temperature in the dark. Cells were then washed, resuspended in PBS and 
immediately acquired by the cytofluorimeter. 5 μl of following antibodies 
conjugates were used: anti-CD4-Phycoerythrin (PE)-Cyanine 7 (Clone 
RPA-T4, IgG1, kappa mouse, eBioscience), anti-CD8-PE-Cyanine 5 (Clone 
RPA-T8, IgG1, kappa mouse, eBioscience), anti-CD38-PE (Clone HB-7, 
IgG1, kappa mouse, BioLegend), anti HLADR-II-fluorescein Isothiocyanate 
(FITC) (Clone Immu-357, IgG1 Mouse, Beckman-Coulter). Unstained 
control sample and single simple stained samples were used for color 
compensation. Cytometric analyses were performed on 200000 events 
using a Gallios500 flow cytometer (Beckman-CoulterFlow). Data were 
analyzed by first gating on the lymphocyte population as defined by forward 
and side light scatters. CD4 or CD8 cells against side scatter were then 
selected and used to evaluate the percentage of positive cells for the 
marker analyzed. Data were analyzed using Kaluza 1.3 software (Beckman 
Coulter). 
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2.2 Intracellular Cytokine Staining and T cell subsets 
detection 
 
After 18 hours of stimulation, cells were centrifuged at 1750 rpm for 10 
minutes at room temperatures. Cells were then resuspended in PBS and 
stained with fluorochrome-labeled monoclonal antibodies for 15 minutes, in 
dark and at room temperature. Cells were then fixed in 1% 
paraformaldehyde (PFA) (Sigma-Aldrich), permeabilized with 0,5% saponin 
(Sigma-Aldrich) and stained for intracellular antigens and cytokines for 45 
minutes, on ice and in dark. Cells were washed with PBS and then fixed in 
1% PFA (Sigma-Aldrich). 5μl of following antibodies conjugates were used: 
anti-CD4-PE-Cyanine 7 (Clone RPA-T4, IgG1, kappa mouse, eBioscience), 
anti-RORγT-PE (Clone AFKJS-9, IgG2a Rat, eBioscience) anti-IL-17A-
FITC (Clone eBio64DEC17, IgG1, kappa mouse, eBioscience). Unstained 
control sample and single simple stained samples were used for color 
compensation. Data were acquired by a Gallios500 flow cytometer 
(Beckman-Coulter) and analyzed by first gating on the lymphocyte 
population as defined by forward and side light scatters. CD4 or CD8-
positive cells against side scatter were then selected and used to evaluate 
the percentage of positive cells for the marker analyzed. Data were 
analyzed using Kaluza 1.3 software (Beckman Coulter). 
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3. GENE EXPRESSION ANALYSIS 
 
3.1 Total RNA Extraction 
 
Total RNA was extracted by using the acid guanidium thiocyanate-phenol- 
chloroform method. 1x106 of freshly isolated PBMCs were immediately 
lysed by 200 μl of RNAzol B reagent (Duotech, Milan, Italy). LPS-stimulated 
PBMCs (1x106cells) and their relative non-stimulated control (1x106 cells) 
were lysed by 200 μl RNAzol B reagent after 3 hours of stimulation, 
whereas AT2-treated HIV-1BaL-stimulated PBMCs (1x106cells) and their 
relative non-stimulated control (1x106cells) were lysed by 200 μlRNAzol B 
reagent after 24 hours of stimulation. RNAzol B reagent (Duotech, Milan, 
Italy) is a monophase solution containing phenol and guanidine 
thiocyanate. After cellular lysis, chloroform (20% of initial volume of RNAzol 
B) was added to separate the lysate into aqueous and organic phase. 
Samples were then centrifuged at 12,000g 15 minutes at 4°C and DNA and 
proteins were separated from the aqueous phase containing RNA. The 
aqueous phase containing RNA was collected and transferred to a sterile 
tube and an equal volume of isopropanol was added. Samples were then 
stored at -20°C overnight to allow complete precipitation of RNA. 
The day after, samples were heated at 4°C for 15 minutes and centrifuged 
at 13000g for 15 minutes. Supernatant was removed and RNA pellet was 
washed with 100μl of 75% ethanol twice. Subsequently the sample was 
centrifuged for 8 minutes at 12000g at 4°C. Supernatant was removed and 
the pellet was dried and dissolved in RNAse-free water (Sigma-Aldrich). 
The quality of RNA was tested using Nanodrop Spectrophotometer. 
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3.2 DNAse treatment 
 
The RNA was treated with DNAse to eliminate contamination of genomic 
DNA. For each sample a reaction mix was prepared containing 1μg of 
RNA, 2 μl of DNAse 2U/μl (New England Biolabs), 1.15 μl of 10x DNAse 
buffer (10mM TRIS-HCl ph 7.5, 25mM MgCl2, 5mM CaCl2), 0.35 μl 1U/μl 
RNAsi inhibitor (20 U, Promega) and pure water up to 11.5 μl of final 
volume. Reaction mix was incubated at 37°C for 30 minutes. 1μl of EDTA 
60 mM (Ambion Inc., Austin, Texas, USA) was added to each sample to 
stop DNAsi action at 75°C for 10 minutes. 
 
3.3 Retrotranscription 
 
1 μg of RNA was reverse transcribed into first-strand cDNA in a 20-μl final 
volume. A reaction mixture, containing 1 μM random hexanucleotide 
primers, 1 μM oligo dT and the RNA, was heated at 70 °C for 5 minutes to 
melt secondary structure within the template. The mixture was immediately 
cooled on ice to prevent secondary structure from reforming. A dNTPs mix, 
200 U Moloney murine leukemia virus reverse transcriptase (M-MLV RT), 
20 U Recombinant RNasi inhibitor and M-MLV 5X reaction buffer were 
added (Promega, Fitchburg, WI, USA). The reaction mix were incubated 60 
minutes at 42 °C and then heated 5 minutes at 95 °C to inactivate the RT. 
Each cDNA sample was diluted 1:8 in RNAse and DNAse free water 
(Sigma-Aldrich) and stored at -20°C. 
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3.4 Real-Time PCR Array 
 
Inflammasome signalling pathways were analyzed in a PCR array including 
a set of optimized real-time PCR primer assays on 96-well plates 
(SABiosciences Corporation, Frederick, MD, USA) according to 
manufacturer’s instructions. This approach permits the monitoring of mRNA 
expression of 84 genes (Table 1) related to the inflammasome pathway, 
plus housekeeping genes, following the procedures suggested by the 
manufacturer. Controls were also included on each array for genomic DNA 
contamination, RNA quality, and general PCR performance. The results 
were analyzed by SABioscences online software and GAPDH and β-Actin 
were used as housekeeping genes. Only targets showing at least a 2-fold 
modulation were considered significant. The experiments have been run on 
samples pooled into two distinct groups (INRs and IRs) on the basis of 
condition (LPS stimulation and relative untreated control and AT2-treated 
HIV-1Bal stimulation and relative untreated control). Thus, results represent 
the mean value of the different targets analyzed in each group. The 
expression of some targets that showed a modulation equal to nfold>2 
were confirmed by Real time PCR on each individual sample. 
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Functional Gene Grouping Genes 
Toll-like Receptor (TLR) 
Signaling: 
Receptors & Cofactors: CD14, LY96 (MD-2), TLR1, TLR2, TLR4, 
TLR5, TLR6, TLR9. 
MYD88-Dependent: FADD, IRAK1, IRAK3, IRF5, IRF7, MAP3K7 
(TAK1), MYD88, TIRAP, TLR1, TLR2, TLR4, TLR5, TLR6, TLR9, 
TOLLIP, TRAF6. 
TICAM1 (TRIF) Dependent (MYD88-Independent): IRF5, IRF7, 
MAP3K7 (TAK1), RIPK1, TICAM1 (TRIF), TICAM2 (TRAM), TLR4, 
TRAF6.  
Other: AKT1, CASP8 (FLICE), LBP, PIK3CA (p110a), RAC1 
NOD-like Receptor (NLR) 
Signaling: 
Receptors: NAIP (BIRC1), NLRC4 (IPAF), NLRP1, NLRP3, NOD1 
(CARD4), NOD2. 
Inflammasomes: CASP1 (ICE), NAIP (BIRC1), NLRC4 (IPAF), NLRP1, 
NLRP3, PYCARD (TMS1/ASC). 
Regulation: BIRC3 (c-IAP1), CARD6, CARD9, CASP8 (FLICE), 
HSP90AA1, MEFV, PSTPIP1,RIPK2, SUGT1, TNF, XIAP 
Other Bacterial Pattern 
Recognition Receptors 
(PRRs): 
APCS, CRP, DMBT1, ZBP1. 
 
Downstream Signal 
Transduction: 
NF?B Pathway: CHUK (IKKa), IKBKB, NFKB1, NFKBIA (IkBa/MAD3), 
RELA, TNFRSF1A. 
ERK Pathway: JUN, MAP2K1 (MEK1), MAPK1 (ERK2), MAPK3 
(ERK1). 
p38/JNK Pathway: JUN, MAP2K3 (MEK3), MAP2K4 (JNKK1), 
MAPK14 (p38 MAPK), MAPK8 (JNK1). 
Apoptosis: AKT1, BIRC3 (c-IAP1), CARD6, CARD9, CASP1 (ICE), CASP8 
(FLICE), CD14, FADD, IFNB1, IKBKB, IL12A, IL12B, IL1B, IL6, IRAK1, 
JUN, MAP3K7 (TAK1), MAPK1 (ERK2), MAPK8 (JNK1), MPO, NFKB1, 
NFKBIA (IkBa/MAD3), PIK3CA, PYCARD, RAC1, RIPK1, RIPK2, TNF, 
TNFRSF1A, TRAF6. 
InflammatoryResponse: AKT1, APCS, CCL3 (MIP-1A), CCL5 (RANTES), CD14, CRP, CXCL1, 
CXCL2, IL1B, IL6, IL8, LBP, LY96 (MD-2), LYZ, MEFV, MYD88, 
NFKB1, NLRC4, NLRP3, NOD1 (CARD4), RAC1, RELA, RIPK2, 
SLC11A1, TICAM2 (TRAM), TIRAP, TLR1, TLR2, TLR4, TLR5, TLR6, 
TLR9, TNF, TNFRSF1A, TOLLIP. 
Cytokines&Chemokines: CCL3 (MIP-1A), CCL5 (RANTES), CXCL1, CXCL2, IFNA1, IFNB1, 
IL12A, IL12B, IL18, IL1B, IL6, IL8. 
AntimicrobialPeptides: BPI, CAMP, CTSG, LCN2 (NGAL), LTF, LYZ, MPO, PRTN3, SLPI 
 
Table 1: List of genes in the real-time PCR Array. (SABioscience) 
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3.5 Real-Time PCR 
 
cDNA quantification of genes involved in this study was performed by real-
time PCR (CFCX Connect Bio-Rad). Reactions were performed using a 
SYBR Green PCR mix (iTaqTM Universal SYBR Green Supermix, Bio-Rad). 
SYBR green is a fluorogenic minor groove binding dye that exhibits little 
fluorescence when in solution but emits a strong fluorescent signal upon 
binding to double-stranded DNA. Mixes were prepared according to Table 
2: 
 
Component Volume per 1 Reaction 
Primer Mix (Forward and Reverse) 10 μM 0.5 μl 
iTaqUniversalTM SYBR Green® Supermix 5 μl 
cDNA 2 μl 
Nuclease-free water 2.5 μl 
Final volume 10 μl 
 
Table 2: Individual Real-Time PCR reaction setup 
 
Reactions were performed according with the following thermal profile: an 
initial activation step (95 °C, 2 minutes) followed by 40 cycles of 5 seconds 
at 95 °C (denaturation) and 30 seconds at 60 °C (annealing and extension). 
Melting Curve analysis was performed for each reaction at 65°-95°C (0.5 
°C increments) 5 sec/step. By recording the amount of fluorescence 
emission at each cycle, the PCR reaction was monitored during exponential 
phase, where the first significant increase in PCR product correlates to the 
initial amount of target template. The higher the starting copy number of the 
nucleic acid target, the sooner a significant increase in fluorescence is 
observed. The threshold line is the level of the detection or the point at 
which the reaction reaches a fluorescent intensity above background (the 
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mean of fluorescence values detected from to third to tenth cycle, when 
target amplification it is no appreciable yet). The parameter Ct (Threshold 
cycle) is defined as the fractional cycle number at which the fluorescence 
passes the fixed threshold. The higher the initial amount of cDNA, the 
sooner accumulated product is detected in the PCR process, and the lower 
the Ct value. GAPDH and β-Actin were used as housekeeping genes and 
the mean Ct of these two genes was used as housekeeping gene. Results 
are expressed as fold change 2ΔΔCt and were calculated according to 
Livak’s method [299]. Primers used are shown in Table 3. For detection of 
NLRP3, Caspase-1 (CASP1), Caspase-3 (CASP3), Caspase-4 (CASP4), 
Caspase-5 (CASP5) and IFI16 primers were purchased already optimized 
by Bio-Rad (PrimePCR). 
 
Gene Primer Forward Primer Reverse 
IFNγ GGCGACAGTTCAGCCATCAC TGTGGAGACCATCAAGGAAGACA 
TNFα TCTTCTCGAACCCCGAGTGA CCTCTGATGGCACCACCAG 
IL-6 GGTGTTGCCTGCTGCCTTC GCCAGTGCCTCTTTGCTGCT 
CCL3 ATGGCTCTCTGCAACCAGTTC AGCACAGACCTGCCGGCTTCG 
GAPDH CGGATTTGGTCGTATTGGG GCTTCCCGTTCTCAGCCTTG 
KI67 TGTGTTGGATTTGTGGAACTGA CACCTGCTTGTTTGGAAGGG 
β ACTINA ATGCCCAGGAAGGAAGGCTG GGGAAATCGTGCGTGACATT 
IL-1β TTCTGCTTGAGAGGTGCTGATG TGTCCTGCGTGTTGAAAGATGA 
IL-18 GCTGCTGAACCAGTAGAAGAC CCGATTTCCTTGGTCAATGAAGA 
IFNβ CAGGCCGCATTGACCATCTA GACATTAGCCAGGAGGTTCTCA 
 
Table 3: Primers sequences used in Real-Time PCR experiments. 
Primers were purchased from Sigma-Aldrich.  
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4. ELISA ASSAYS 
 
4.1 Plasma LPS quantification 
 
LPS concentration was measured on plasma samples from each subject 
included in the study. LPS was measured by Limulus Amebocyte Lysate 
(LAL) Chromogenic Endpoint Assay (Hycult Biotechnology, Uden, The 
Netherlands). The assay is based on Frederick Bang’s observation that the 
endotoxin of bacteria caused intravascular coagulation in the American 
horseshoe crab (Limulus polyphemus) [300]. Levin, Bang and coworkers 
then found that the coagulation was due to an enzyme in the circulating 
blood cells of the crab (amoebocytes) and that the reaction was initiated by 
the endotoxin itself [301]. In the chromogenic LAL assays, LPS activates 
LAL clotting enzyme, however the original enzyme’s substrate - the clotting 
protein - is removed and replaced by a chromogenic substrate, such as p-
nitroaniline, which will cause a yellow colour to develop upon cleavage. The 
chromophore contains an amino acid sequence which is similar to that 
present in the clotting protein cleaved by the enzyme. The absorbance will 
be indirectly a function of the amount of endotoxin present in the sample 
[302]. Measuring LPS in biological fluids, such as plasma, is challenging as 
many factors can inhibit endotoxins, nowadays chromogenic LAL assay is 
considered to be the best option available as it compromises increased 
sensitivity with relative convenience of operation [303]–[305]. 
Samples, standards and reagents were prepared according to 
manufacturer’s instructions. Plasma samples were heated at 75°C for 5 
minutes in order to neutralize endotoxin inhibiting compounds. Plasma 
samples were then diluted 1:5 in endotoxin free water. 50μl of each diluted 
sample and standard were plated in duplicate in a 96-well plate and 
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immediately 50μl of LAL reagent was added in each well. After 30-minutes 
incubation at room temperature, reaction was stopped with 50μl of stop 
solution. Absorbance was measured at 415nm with a spectrophotometer 
(iMark Bio-Rad). The blank optical density was subtracted from the average 
of duplicate readings for each standard and sample. The standard curve 
was constructed by plotting the optical density on the y-axis against the 
concentration of the standards on the x-axis (logarithmic scale) using iMark 
Bio-Rad Software. LPS concentration was calculated relatively to the 
standard curve, multiplied by the dilution factor, expressed in EU/ml. 
 
4.2 Plasma sCD14 quantification 
 
Soluble CD14 (sCD14) was measured by Quantikine ELISA Kit (R&D), 
following manufacturer’s instructions. Samples were diluted 1:400 in 
Calibrator Diluent RD5P. 100μl of Assay Diluent RD1W (provided in the kit) 
were added to each 96-well pre-coated with anti-sCD14 antibody. 100μl of 
standards and sample were added per well in duplicate. Samples were 
then incubated for 3 hours at room temperature. Plate was washed4 times 
using an autowasher. 200μl of sCD14 Conjugate were added to each well 
and the plate was incubated for 1 hour at room temperature. After 4 
washes, 200 μl of substrate solution were added to each well and 
incubated for 30 minutes at room temperature in dark. Finally, 50 μl of stop 
solution were added to each well and the plate was read at 450 nm with 
wavelength correction set to 540 nm. Standard Curve was created by 
generating a four parameter logistic curve-fit using iMark Bio-Rad software. 
The blank optical density was subtracted from the average of duplicate 
readings for each standard and sample. Concentrations from standard 
curve were then multiplied by dilution factor.  
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4.3 Plasma IL-18 Quantification 
 
IL-18 was measured by ELISA, following manufacturer’s instructions (MBL, 
Japan). Each sample was diluted 1:5 in Assay Diluent provided by the kit. 
150μl of diluted samples and standards were transferred to a 96-plate pre-
coated with anti-IL-18 antibody in duplicate. The plate was incubated for 1 
hour at room temperature. The plate was then washed and 100 μl of 
conjugate solution (provided in the kit) were added to each well. The plate 
was incubated for 1 hour at room temperature. After 4 washed, 100 μl of 
Substrate Reagent were added to each well and the plate was incubated 
for 30 minutes at room temperature. The colorimetric reaction was stopped 
by pouring 100 μl of stop solution. Plate was read at 450 nm. The blank 
optical density was subtracted from the average of duplicate readings for 
each standard and sample. Standard Curve was created by generating a 
four parameter logistic curve-fit using iMark Bio-Rad software. 
Concentrations from standard curve were then multiplied by dilution factor. 
 
4.4 Plasma IL-1β Quantification 
 
IL-1β was measured by ELISA, following manufacturer’s instructions 
(DuoSet R&D Systems). Briefly, A 96-well microplate was coated with 100 
μl per of diluted capture antibody (provided in the kit) and incubated 
overnight at room temperature. The day after, plate was washed three 
times and subsequently each well was blocked by adding 300 μl of 
Reagent Diluent (provided in the kit) at room temperature for 1 hour. Plate 
was then washed twice. 100 μl of undiluted samples or of standards were 
added in duplicate to the plate and incubated for 2 hours at room 
temperature. Plate was washed three times and 100 μl of Detection 
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antibody were added to each well and incubated for 2 hours at room 
temperature. Plate was then washed three times and 100 μl of diluted 
Streptavidin-HRP Solution was added to each well and incubated for 20 
minutes at room temperature in the dark. Plate was washed 3 times and 
100 μl of Substrate Solution was added to each well and incubated for 20 
minutes at room temperature in the dark. 50 μl of Stop Solution were added 
to each well and optical density was immediately determined at 450 nm 
with wavelength correction set at 595 nm. The blank optical density was 
subtracted from the average of duplicate readings for each standard and 
sample. Standard Curve was created by generating a four parameter 
logistic curve-fit using iMark Bio-Rad software. Concentrations were 
calculated from standard curve. 
Plasma IL-1β was undetectable in some samples, therefore for samples 
that could not be detected by using a standard IL-1β ELISA, we used a IL-
1β High Sensitivity ELISA kit following manufacturer’s instructions 
(Quantikine HS ELISA R&D Systems). Briefly, 100 μl of Assay Diluent 
(provided in the kit) were added to each well of a 96-well pre-coated with 
anti-IL1β antibody and then 150 μl of standards or samples were added to 
each well and incubated for 3 hours at room temperature on an horizontal 
shaker. Plate was then washed six times and 200 μl of high sensitivity 
conjugate (provided in the kit) was added to each well and incubated for 2 
hours at room temperature on an horizontal shaker. Plate was washed for 
six times and 50 μl of Substrate Solution was added to each well and 
incubated 1 hour at room temperature on an horizontal shaker. Then, 50 μl 
of Amplifier solution was added to each well and incubated for 30 minutes. 
50 μl of stop solution were then added to each well and optical density was 
immediately assayed by reading the plate at 490 nm with wavelength 
correction set at 655 nm. The blank optical density was subtracted from the 
average of duplicate readings for each standard and sample. Standard 
Curve was created by generating a four parameter logistic curve-fit using 
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iMark Bio-Rad software. Concentrations were calculated from standard 
curve. 
 
4.5 Plasma IL-6 Quantification 
 
IL-6 was measured in plasma by Quantikine High Sensitivity ELISA Kit 
according to manufacturer’s instructions(R&D). Briefly, 100 μl of Assay 
Diluent (provided in the kit) were poured into each well of a 96-well plate 
pre-coated with an antibody anti-IL-6. 100μl of standard or samples were 
added per well and the plate was incubated for 2 hours at room 
temperature on a horizontal orbital microplate shaker at 500 rpm. After 6 
washes, 200 μl of IL-6 conjugate (provided in the kit) were added to each 
well and the plate was incubated for additional 2 hours, followed by 6 
washes. 50μl of substrate solution was added to each well and the plate 
was incubated for 1 hour. Given that IL-6 levels in plasma are low, it is 
necessary to amplify the signal generated by the substrate solution. For this 
reason, 50 μl of amplifier solution (provided in the kit) were added to each 
well and the plate was incubated for additional 30 minutes. Finally, 50 μl of 
stop solution were added to each well. The plate was read at 490 nm with 
wavelength correction set to 655 nm. The blank optical density was 
subtracted from the average of duplicate readings for each standard and 
sample. Standard Curve was created by generating a four parameter 
logistic curve-fit using iMark Bio-Rad software. Concentrations were 
calculated from standard curve. 
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4.6 Plasma Caspase-1 Quantification 
 
Caspase-1 is a IL-1β-converting enzyme (ICE), which is synthesized as an 
inactive precursor. Active caspase-1 is generated by dimerization and 
proteolysis and it produced an enzyme composed of two large (20 KDa) 
and two small (10 KDa) subunits and the active enzyme contains 2 active 
sites [306].In order to detect it in plasma we used a ELISA Kit (Quantikine, 
R&D), which allows the specific detection of the p20 subunit of caspase-1. 
Briefly, 50 μl of Assay Diluent (provided in the kit) were added to each well 
of a 96-plate previously coated with an antibody anti-caspase-1 p20 
subunit. Samples were diluted 1:2 and then 100 μl of samples and 
standards were added into each well and incubated 1,5 hours at room 
temperature. Plate was then washed three times and 100 μl of caspase-1 
antiserum was added to each well and incubated for 30 minutes at room 
temperature. Plate was then washed three times and 100 μl of caspase-1 
conjugate was added to each well and incubated at room temperature. 
Plate was then washed and 200 μl of substrate solution was added to the 
plate and incubated for 20 minutes at room temperature. 50 μl of stop 
solution was added into each well and optical density was immediately read 
at 450 nm. Standard Curve was created by generating a four parameter 
logistic curve-fit using iMark Bio-Rad software. Concentrations were 
calculated from standard curve. 
 
5. STATISTICAL ANALYSIS 
 
Parametric (unpaired Student T test) and nonparametric (Mann Whiney) t-
tests were performed to compare INRs and IRs. Samples distribution were 
assessed by KS normality test. Statistical analysis were performed using 
GraphPad Prism analysis software.  
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1. STUDY POPULATION 
 
In this study 39 HIV+ ART-treated patients were enrolled at the Unit of 
Infectious Diseases, San Gerardo Hospital, Monza – Italy. Demographic 
and clinical characteristics are summarized in Table 4. All patients were 
virologically suppressed as plasma viral load was at undetectable levels 
(plasma HIV-RNA <50 cp/mL) for at least 12 months. Patients were divided 
into two groups according to their CD4+ T cell counts: Immunological 
Responders (IR, CD4+ T cell count >500 cells/µl) and Immunological Non 
Responders (INR, CD4+ T cell count <350 cells/µl). INRs were older 
(median 60 vs. 43 years, p<0.001) and showed a higher rate of past AIDS-
defining events, probably due to their low CD4+ T cell counts (76.5% vs. 
18.2%, p<0.001). Older age is associated with lower CD4+ T cell counts 
and poorer immunological response to HAART [307].  
Older individuals have a higher background of immune activation and this 
could contribute to inadequate immune recovery during HAART. Median 
CD4 count was 840 (IQR 718-1131) cells/µL in IR vs. 295 (IQR 256-343) 
cells/µL in INR. 
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  IR (n=22)  INR (n=17)  P  
Age 43 (40-48)  60 (50-66)  <0.001  
Male gender 16 (72.7)  14 (82.4)  0.704  
Caucasian 19 (86.4)  14 (82.4)  1.000  
Riskfactor:     0.769  
Heterosexual 11 (50)  10 (58.8)    
Homosexual 5 (22.7)  4 (23.5)    
Unknown 6 (27.3)  3 (17.6)    
Years from HIV diagnosis 9.3 (6.2-20.2)  10.2 (3.8-15.6)  0.557  
Past AIDS-definingevents 4 (18.2)  13 (76.5)  <0.001  
CD4 840 (718-1131)  295 (256-343)  <0.001  
CD4% 34 (28-40)  19 (16-21)  <0.001  
CD8 1139 (781-1383)  685 (489-899)  0.001  
CD8% 41 (36-47)  48 (37-53)  0.300  
CD4/CD8 0.81 (0.60-1.03)  0.41 (0.29-0.58)  <0.001  
CD4/CD8 >1 6 (27.3)  0  0.027  
Months from last VL>50 53.7 (33.4-67.7)  59 (25.9-84.9)  0.617  
Years from cART initiation 7.7 (4.8-11.2)  10.2 (3.3-13.4)  0.540  
Months from last regimen 
initiation 
48.5 (18.2-60.9) 16.8 (5.5-41.2) 0.209 
NRTI 20 (90.9) 16 (94.1) 1.000 
NNRTI 12 (54.5) 7 (41.2) 0.613 
PI 6 (27.3) 6 (35.3) 0.851 
InSTI 6 (27.3) 7 (41.2) 0.568 
EI 0 0 nc 
 
Table 4: Clinical and demographic characteristics of HIV-infected 
patients enrolled in the study . Median and interquartile ranges are 
shown. VL: viral load. cART: combinational antiretroviral therapy. 
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2. T-CELL IMMUNE ACTIVATION 
 
The main hallmarks of T cell immune activation during HIV infection are the 
expression of HLA-DR II molecules on CD4+ T cells and of CD38 antigen 
on CD8+ T cells [58], [308]. HLA-DRII is constitutively expressed on APCs 
and, during immune responses, it is expressed only on a subset of 
activated T cells and it is a marker of HIV disease progression [48]. CD38 is 
constitutively expressed by naïve T cells and it is down-regulated on 
memory cells and up-regulated on activated cells. It has been reported by 
several studies that the persistent immune activation of T cells during HIV 
infection leads to depletion of the naïve CD4+ T cell and CD8+ T cell pools 
[27], [309]. Therefore, we decided to conduct a immune phenotypic 
analysis in order to evaluate the basal immune activation status in the two 
groups. In particular, we analyzed HLA-DRII expression on CD4+ T cells 
and CD38+ expression on CD8+T cells in IRs and INRs. Results are shown 
in Figure 17 and are expressed as percentage of CD4+/HLA-DRII+ T cells 
and of CD8+/CD38+ T cells. 
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Figure 17: T-cell Immune Activation in IR and INR patients. Panel 
A: percentage of HLA-DRII+CD4+T cells in INRs and IRs. Panel B: 
percentage of CD38+CD8+T cells in INRs and IRs. Mean values and 
SEM are shown. *= p< 0.05.  
 
We observed that INRs show a significant higher percentage of activated 
CD4+ T cells and a trend of increased percentage of CD38+/CD8+ T-cells as 
well. These data indicate that INR individuals, even in presence of no 
detectable viremia, are more immune activated than IR individuals and this 
observation is in agreement with previous findings [129], [48], [142]. 
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3. NLRP3 INFLAMMASOME ACTIVATION 
 
It has been established that chronic immune activation in HIV infection has 
deleterious effects on the immune system by inducing maturation, 
differentiation and activation of many innate and adaptive immune cells 
[48]. In addition Bandera et al., recently suggested that innate immunity 
may play an important role in immune activation [74]. Indeed, recent reports 
indicate that inflammasome activation, especially NLRP3 inflammasome, 
may play a role in HIV infection and in CD4+ T cell depletion [274], [290]. In 
addition a mutation in NLRP3 was associated with higher levels of 
susceptibility to HIV infection [271]. Despite these evidences, 
inflammasomes’ role in HIV pathogenesis and during chronic infection has 
not yet been elucidated. For these reasons we decided to evaluate 
inflammasome activation in IR and INR patients.  
 
3.1 NLRP3 expression in unstimulated PBMCs 
 
NLRP3 expression was evaluated by real-time PCR in unstimulated 
PBMCs from IR and INR patients. Results (Figure 18) were calculated 
relative to the mean expression of housekeeping genes GAPDH and β-
actin and they are shown as fold change expression. 
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Figure 18: NLRP3 mRNA expression in unstimlatd PBMCs from IR 
and INR patients. Mean values and SE are shown.**= p< 0.01  
 
We observed a significant (p<0.01) increase in NLRP3 gene expression in 
INRs compared to IRs, suggesting a higher rate of inflammasome 
activation in these patients.  
 
3.2. Inflammasome Pathway Gene Expression 
 
Inflammasome pathway gene expression was further evaluated in PBMCs 
either unstimulated or stimulated with LPS or with AT2-treated HIV-
1BaLvirions. LPS is known to induce inflammasome expression [220]. We 
also wanted to evaluated if HIV is able to induce inflammasome activation 
in the settings of chronic infection and for this reason AT2-treated HIV-
1BaLvirions were used as well. 
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3.2.1 Inflammasome Pathway Gene Expression in LPS-stimulated 
PBMCs 
 
To evaluate the inflammasome pathway gene expression in LPS-stimulated 
PBMCs, we performed a Real-Time PCR Array screening of 84 genes. 
Results are shown in Figure 19 and only targets showing a nfold>3 were 
considered significant. We could not find significant differences in the 
expression levels of unstimulated PBMCs, however INRs were more 
responsive to LPS stimulation than IRs: in particular, we observed an up-
regulation of NLRP3, caspase-1 (CASP1), IL-1β and IL-18 in INRs 
compared to IR. These data suggest that inflammasome expression and 
possibly activation is higher in INRs. Interestingly, an up-regulation of many 
pro-inflammatory cytokines and chemokines (CCL3, CXCL2, IL12A, IL6) 
and of other genes associated with signal transduction and cell death 
(IFNB1, RIPK1, RIPK2, TRAF6, XIAP, ZBP1 and TNF) was detected in 
INRs compared to IRs. 
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Nfold>3 Gene INR IR 
 CASP1 3.5 1.5 
CCL3 30.2 5.3 
CXCL1 9.06 1.54 
CXCL2 25.9 1.78 
IFNB1 8.1 2.7 
IL12A 6.1 1.3 
IL1B 3.8 1.18 
IL18 3.8 1.16 
IL6 8.04 7.5 
IL8 8 1.7 
NLRP3 3.5 1.19 
RIPK1 6.3 1 
RIPK2 8.6 1 
TRAF6 4.6 1 
XIAP 3.3 1.4 
ZBP1 4.2 1.6 
TNF 8.5 1.8 
 
Figure 19: Real-Time PCR Array on LPS-stimulated PBMCs in INR 
and IR HIV-infected patients. Gene expression (nfold) is shown as a 
color scale from green to red (-85 to +85) (MEV multiple experiment 
viewer software). Only targets showing >3-fold modulation are 
considered significant and are shown in table. Nfold LPS-stimulated 
PBMCs vs unstimulated PBMCs 
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3.2.2 Gene Expression Profile in LPS-stimulated PBMCs 
 
To confirm the results obtained in the array analysis and to further 
characterize the gene expression profile, we evaluated some targets by 
Real-Time PCR on each subject included in the study. In particular, we 
evaluated the expression of several pro-inflammatory cytokines and 
chemokines such as IL-1β, IL-18, TNF-α, IFN-γ, IFN-β and CCL3 (Figure 
20). 
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Figure 20: Gene expression profile of pro-inflammatory cytokines 
in LPS-stimulated PBMCs from IR and INR HIV-infected patients. 
IL-1β, IL-18, TNFα, IFNβ, IFNγ and CCL3 expression was evaluated in 
IRs (white bar) and INRs (black bar). Mean values and SE are shown. 
*= p< 0.05; **= p< 0.01 
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Results are shown as fold change expression and were calculated relative 
to the mean expression of housekeeping genes GAPDH and β-actin and 
relative to one calibrator untreated sample, according to Livak’s method 
[299]. We observed a significant increase in inflammasome-related 
cytokines and other pro-inflammatory cytokines expression in INR patients, 
thus confirming the array results. In particular, we showed an increase in 
IL-1β (p <0.05) and IL-18 (p <0.01), suggesting a higher activation rate of 
inflammasome pathway in INR patients than in IRs, as well as higher 
activation rate of immune system and thus of immune activation in 
immunological non-responders. 
 
3.2.3 Inflammasome Pathway Gene Expression in AT2-treated HIV-
1BaL-stimulated PBMCs 
 
The same type of analysis was performed on AT2-treated HIV-1BaL-
stimulated PBMCs in order to evaluate inflammasome response to HIV in 
the two groups of patients.  
As expected, HIV stimulation was less efficient in triggering inflammasome 
activation compared to LPS, probably due to the chronic infection settings, 
which may lead to exhaustion of immune system itself (Figure 21). 
However, we could still detect an up-regulation of NLRP3 and caspase-1 
(CASP1) in both groups of patients, suggesting that, even in a scenario of 
chronic infection, HIV is able to stimulate NLRP3inflammasome activation. 
Interestingly, IFN-α and IFN-β were up-regulated in IRs, but not in INRs. 
Type I interferons are known to be important for immune responses against 
viruses, so the lack of Type I interferon up-regulation in response to HIV 
stimulation in INRs may indicate that, in these patients, HIV-specific 
responses against HIV is particularly skewed.  
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Nfold>2 Gene INR IR 
 CASP1 2.26 2.09 
 DMTB1 -3.18 5.95 
 IFNA1 3.97 174.56 
 IFNB1 4.47 185.53 
 IL12B -18.07 13.66 
 IRF7 6.73 8.77 
 MEFV 2.99 5.57 
 MPO -3.24 7.32 
 MYD88 1.74 3.03 
 NLRP3 1 2.13 
 
 
Figure 21: Real-Time PCR Array on AT2-treated HIV-1BaLvirions-stimulated 
PBMCs in INR and IR HIV-infected patients. Gene expression (nfold) is shown 
as a color scale from green to red (-18 to +20) (MEV multiple experiment viewer 
software). Only targets showing >2-fold modulation are considered significant and 
are shown in table. Nfold AT2-treated HIV-1BaL virions-stimulated PBMCs vs. 
unstimulated PBMCs 
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3.2.4 Gene Expression Profile in AT2-treated HIV-1BaL-stimulated 
PBMCs 
 
To confirm the results obtained in the array analysis and to further 
characterize the gene expression profile, we evaluated some targets by 
Real-Time PCR on each subject included in the study. In particular, we 
evaluated the expression of several pro-inflammatory cytokines such as IL-
1β, IL-18, TNF-α, IFN-γ and IL-6. NLRP3 expression was also evaluated in 
order to confirm if NLRP3 inflammasome could be induced directly by HIV. 
(Figure 22).  
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Figure 22: Gene expression profile of pro-inflammatory cytokines 
in AT2-treated-HIV-1BaL-stimulated PBMCs from IR and INR HIV-
infected patients. NLRP3, IL-1β, IL-18, IFNγ, IL-6 and TNFα mRNA 
expression in IRs (white bar) and INRs (black bar). Mean values and 
SE are shown. *= p< 0.05; **= p< 0.01.  
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Results are shown as fold change expression and were calculated relative 
to the mean expression of housekeeping genes GAPDH and β-actin and 
relative to one calibrator untreated sample, according to Livak’s method 
[299]. We observed that NLRP3 and IL-18 were significantly more 
expressed in INRs compared to IRs (p<0.05 and p<0.01, respectively), 
suggesting that NLRP3 inflammasome pathway induction by HIV is 
increased in INRs. We could detect a higher expression of IL-1β in INRs 
too, even though it was not statistically significant. Interestingly, IL-6 was 
not increased in INRs, confirming the array data. IFN-γ expression was also 
lower in INRs compared to IRs. IFN-γ is important in the control of viral 
infections, as it prevents viral spreading by activating innate immune 
phagocytic cell activities. The fact that IFN-γ was lower in INRs may 
suggest, once again, that the immune response to HIV is particularly 
impaired in these patients.  
We could not detect any differences in the gene expression levels of 
unstimulated PBCMs, except for NLRP3, as shown in paragraph 3.1. 
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4. CASPASES, IFI16 AND PRO-INFLAMMATORY 
CYTOKINES EXPRESSION PROFILE 
 
Inflammasome activation leads to the activation of caspase-1, which is able 
to mediate activation of both IL-1β and IL-18 and pyroptosis. We decided to 
evaluate caspase-1 expression in samples from INRs and IRs. In particular, 
we evaluated caspase-1 expression in unstimulated, LPS- and AT2-
treated-HIV-1BaL-stimulated PBMCs. Results are shown (Figure 23) as fold 
change (2ΔΔCt) expression and were calculated relative to the mean 
expression of housekeeping genes GAPDH and β-actin and relative to one 
calibrator untreated sample, according to Livak’s method [299]. 
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Figure 23: Caspase-1 expression in unstimulated, LPS- or AT2-
treated HIV-1BaL stimulated PBMCs in IRs and INRs.Caspase-1 
expression in IRs (white bar) and INRs (black bar). Mean values and 
SE are shown. *= p< 0.05; **= p< 0.01.  
 
Casapse-1 expression was increased in INRs, in each condition analyzed. 
These data suggest that, indeed, inflammasome activation is higher in INRs 
compared to IRs. In addition, these data is in agreement with the array data 
previously reported. Caspase-1 up-regulation in INRs in each culture 
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condition is of particular interest because it strongly suggests that these 
patients could be exposed to cellular death by pyroptosis more than IRs.  
Given the gene expression results, we decided to further investigate 
caspase-1 expression in INRs and IRs (Figure 24) and for this purpose 
plasma levels of caspase-1 were quantified in IRs and INRs. Although, 
statistical significance was not reached, INRs showed higher levels of 
caspase-1 (median IRs 375.3 pg/ml vs. median INRs 526.7 pg/ml), 
suggesting an increased susceptibility to cell death by pyroptosis. 
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Figure 24: Plasma quantification of caspase-1 in IR and INR 
patients.Caspase-1 expression in IRs ( left) and INRs (right). Median 
values and max and min values of distr ibutions are shown.  
 
To further characterize if inflammasome pathway is upregulated in INRs, 
we decided to evaluate IL-1β and IL-18 plasma levels in each patient 
included in the study. As shown in figure 25, we could not detect any 
differences in IL-18 expression, however we could see an increased IL-1β 
expression in INRs, even if it is not statistically significant. Of note, IL-1β 
detection in plasma is rather tricky as it is not released in high quantities. 
Neverthless, this observation leads us to speculate once more that 
inflammasome NLRP3 is indeed more activated in INRs compared to IRs. 
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Figure 25: IL-18 and IL-1β plasma quantification in IR and INR 
patients.IL-18 and IL-1β expression in IRs (dots) and INRs (squares). 
Horizontal l ines indicate mean values.  
 
To further characterize the inflammatory profile of INRs, we also evaluated 
IL-6 expression in plasma. IL-6 is a pro-inflammatory cytokine and it has 
been considered a predictor of non-AIDS-morbidity in HIV-infected patients 
[312]. Results are shown in Figure 26. We could not detect any differences 
between INRs and IRs in agreement with recently reported data on IL-6 
expression in INRs by Tincati C et al. [313]. 
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Figure 26: IL-6 plasma quantification in IRs and INRs. IL-6 
expression in IRs (dots) and INRs (squares). Horizontal l ines indicate 
mean values.  
 
NLRP3 activation may be induced in a “non classical” pathway by caspase-
11 in mice and by caspase-4 and caspase-5 in humans. Therefore we 
decided to evaluate caspase-4 and caspase-5 expression in unstimulated 
or stimulated with LPS or AT2-treated HIV-1BaL PBMCs. Results were 
calculated relative to the mean expression of housekeeping genes GAPDH 
and β-actin and to a calibrator untreated sample and they are shown 
(Figure 27) as fold change expression, according to Livak’s method [299]. 
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Figure 26: Caspase-4 and Caspase-5 gene expression in 
unstimulated, LPS- and AT2-treated-HIV-1BaL-stimulated PBMCs. 
Caspase 4 (Panel A) and 5 (Panel B) expression in IRs (white bars) 
and INRs (black bars). Mean values and SE are shown  
 
As shown in Figure 26, we could not detect any differences in caspase-4 
and caspase-5 expression between IRs and INRs in none of the conditions 
analyzed. These data suggest that in these cohorts of patients NLRP3 
inflammasome activation may not depend on the “non classical pathway”. 
Next, we decided to evaluate also caspase-3 expression in IRs and INRs. 
Caspase-3 is an apoptotic caspase known to induce cell death by 
apoptosis. We evaluated caspase-3 expression in unstimulated, LPS- and 
AT2-treated HIV-1BaL-stimulated-PBMCs.  
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Figure 28: Caspase-3 gene expression in unstimulated, LPS- and 
AT2-treated-HIV-1BaL-stimulated PBMCs.Caspase-3 expression in IRs 
(white bar) and INRs (black bar). Mean values and SE are shown  
 
We could not detect any differences in caspase-3 gene expression 
between IRs and INRs, suggesting that apoptosis is probably not the main 
cell death pathway in INRs.  
 
IFI16 is a PPR, which recently has been associated with HIV pathogenesis 
[314]. Therefore we decided to evaluate the expression levels of IFI16 in 
IRs and INRs. We evaluated IFI16 expression in unstimulated or LPS- or 
AT2-treated HIV-1BaL-stimulated-PBMCs as shown in Figure 28. Results 
were calculated relative to the mean expression of housekeeping genes 
GAPDH and β-actin and to a calibrator untreated sample and they are 
shown (Figure 29) as fold change expression, according to Livak’s method 
[299]. 
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Figure 29: IFI16gene expression in unstimulated, LPS- and AT2-
treated-HIV-1BaL-stimulated PBMC. IFI16 expression in IRs (white 
bars) and INRs (black bars). Mean values and SE are shown.  
 
We could not detect any differences in IFI16 gene expression between IRs 
and INRs. It should be mentioned that IFI16 expression has been evaluated 
on HLAC model system and it has been suggested that peripheral blood 
cells do not express high levels of this receptor [292], [314]. 
 
 
 
 
 
 
 
 
 
 
 
Results 
109 
 
5. PERIPHERAL TH17 T-CELLS EVALUATION IN IRS 
AND INRS 
 
Inflammasome activation can induce Th17 differentiation as it has been 
demonstrated that IL-1β is necessary for Th17 differentiation [261], [315]. In 
addition, little is known about Th17 role in INRs. Therefore, we decided to 
evaluate Th17 T cells subset in our patients. In order to identify Th17 T 
cells we used a combination of three markers: CD4, RORγT and IL17A. 
RORγT is a transcriptional factor that promotes differentiation of T cells into 
Th17. We evaluated the percentage of IL17A+/RORγT+/ CD4+ T cells in 
PBMCs either unstimulated or stimulated for 18 hours with LPS or AT2-
treated HIV-1BaL. Results are shown in Figure 30. 
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Figure 30: Th17 cells in IRs and INRs. Percentage of Th17 cells 
(CD4+, IL17A+ and RORγT+ cells) in IRs (white plot) and INRs (grey 
plot) in unstimulated, LPS- or AT2-treatedHIV-1BaL-stimulated 
PBMCs. Median values and max and min values of distr ibutions are 
shown. *= p < 0.05; ** = p< 0.01.  
 
INRs showed increased percentages of Th17 T cells in all analyzed 
conditions (basal: IRs vs. INRs p=0.04; LPS: IRs vs. INRs p=0.02; AT2: IRs 
vs. INRs p=0.02). This is somewhat surprising considering that Th17 
depletion in the gut has been reported in HIV infection and has been 
associated with disease progression. On the other hand, our data were 
obtained from peripheral blood cells and evidences of the role of peripheral 
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Th17 T cells during HIV infection are still debated. Yet, Th17 T-cells are 
known for their pro-inflammatory action therefore these data may suggest 
the involvement of this T-cell subset in the mechanisms of persistent 
immune activation that characterize INR patients.  
 
6. MICROBIAL TRANSLOCATION 
 
Recently microbial translocation has been considered one of the main 
drivers of immune activation in HIV-infected patients [91]. Therefore, our 
hypothesis was that microbial translocation could be the main driver of 
inflammasome activation observed in our cohort. To verify this hypothesis 
we quantified sCD14 and LPS levels in plasma from IRs and INRs. sCD14 
and LPS are considered the main hallmarks of microbial translocation and 
increased plasma levels of sCD14 and/or LPS have been associated with 
higher immune activation rates during HIV infection [78].  
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Figure 31: sCD14 and LPS quantification in plasma from INRs and 
IRs.sCD14 (Panel A) and LPS (Panel B) plasma expression in IRs 
(dots) and INRs (squares). Horizontal l ines indicate mean values. 
 
Results 
112 
 
As shown in Figure 31, surprisingly, we could not detect any significant 
differences between IRs and INRs, suggesting that – at least in our cohort 
– microbial translocation does not seem to be the main driver of immune 
and inflammasome activation and that probably other mechanisms come 
into play. Nevertheless, these data are in agreement with a very recent 
report by Tincati C. et al [313], in which the authors reported no significant 
differences in LPS and sCD14 plasma concentrations in INRs (CD4+ T cells 
<350 cells/µl and or ΔCD4+ change from baseline <30%) and IR (CD4+ T 
cells >350 cells/µl and/or ΔCD4+ T cells change from baseline >30%).
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In recent years, HIV infection has been regarded not only as immune 
deficiency syndrome but also as a chronic inflammatory disease and, 
nowadays, systemic chronic immune activation in HIV infection is 
considered one of the main drivers of CD4+ T cell loss. HAART is extremely 
successful in inhibiting viral replication, however it has been extensively 
demonstrated that in HAART-treated HIV-infected patients, immune 
activation and inflammation levels still remain higher than in uninfected 
individuals, making HIV-infected individuals more susceptible to 
cardiovascular diseases and other morbidities [48]. In addition, 
approximately 20% of all HIV-infected individuals fail to restore their CD4+ T 
cells counts despite fully suppressed viral replication: these patients are 
commonly referred to as “immunological non-responders”. INRs display 
higher immune activation and inflammation rates and, for these reasons, 
they are even more susceptible to non-AIDS related morbidity [307]. The 
reasons behind the lack of immune reconstitutions have not been yet fully 
elucidated, even though many factors – such as residual HIV replication, 
impaired CD4+ T-cell production and excessive loss – have been 
associated to this condition. Yet, none of these factors provide a full 
explanation for the lack of immune recovery observed in INRs. Recently, 
Wilson et al. reported in a large study including 670 HIV-infected 
participants, that plasma inflammatory biomarkers were strongly associated 
with monocyte activation and migration and not with CD8+ T-cell activation 
phenotypes [316]. A further study by Bandera et al. suggested that innate 
immune activation contributes to the pathogenesis of inflammation and 
poor immune reconstitution [317]. In addition, many reports have indicated 
a possible role for innate immunity receptors, such as inflammasomes in 
the pathogenesis of HIV and in CD4+ T cell loss [272], [273], [282], [291]. 
Given these premises, we decided to evaluate the possible associations 
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between inflammasomes and T cell activation and the degree of immune 
reconstitution in HIV-infected ART-treated patients.  
To this purpose, we first investigated T cell immune activation by evaluating 
the percentage of HLA-DRII+ and CD38+ cells respectively on CD4+ and 
CD8+ T cells. We observed that INRs had a higher proportion of activated T 
cells, which is in agreement with other scientific reports (reviewed in [48]) 
and confirms the higher immune activation status of these patients.  
Next, we decided to evaluate the basal expression of NLRP3 
inflammasome in PBMCs. We observed a significant increase of NLRP3 
gene expression in INRs. This result is of particular interest because, to this 
date, there are no reports of NLRP3 expression and/or activity in INRs. It 
has been reported that HIV is able to trigger NLRP3 expression upon 
infection, but clear analysis on inflammasome’s role during chronic infection 
are still missing [272]–[274]. Interestingly, only very recently inflammasome 
activation – especially of IFI16 and in part of NLRP3 – has been implicated 
in HIV pathogenesis, suggesting that their activation, especially in the 
lymph nodes, leads to pro-inflammatory cytokine release, such as IL-1β 
and IL-18, and to pyroptosis of CD4+ T cells, which is a form a programmed 
cell-death that, unlike apoptosis, is able to trigger inflammation. Therefore, 
the significant higher expression of NLRP3 in INRs could indicate a higher 
rate of inflammasome and immune activation.  
To better characterize inflammasome activation in IRs and INRs, we 
stimulated PBMCs either with LPS or with AT2-treated HIV-1BaL. LPS is 
known to be a potent activator of inflammasomes’ pathway and we wanted 
to evaluate if HIV-1 could induce NLRP3 expression even in the settings of 
chronic infection. In LPS-stimulated PBMCs we were able to observe that 
INRs were much more responsive to LPS stimulation compared to IRs, 
suggesting a higher immune activation status, with an up-regulation of 
NLRP3 and caspase-1 gene expression. In addition, Real-Time PCR on 
each subject included in the study, showed a significant increased 
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expression of inflammasome-related cytokines, such as IL-1β and IL-18, 
which are directly linked to inflammasome activation. We were also able to 
observe an increase of other pro-inflammatory cytokines and chemokines 
such as IL-6and CCL3. Further, we performed the same type of analysis on 
PBMCs stimulated with AT2-treated-HIV-1BaL. As expected, HIV was less 
efficient in stimulating the inflammasome pathway compared to LPS, which 
is in agreement with other reports. Pontillo A. et al., reported that HIV was 
able to induce NLRP3 gene expression only in dendritic cells from healthy 
individuals but not from HIV-infected individuals, suggesting that HIV was 
able to induce NLRP3 expression upon infection, but that failed to do so in 
chronically activated cells from infected individuals [272]. Interestingly, 
when we evaluated NLRP3 gene expression by individual Real-Time PCR, 
we observed a significant up-regulation of NLRP3 in INRs compared to IRs, 
suggesting that in INRs HIV is able to significantly elicit NLRP3 expression. 
Further to that, we also evaluated by individual Real-Time PCR if IL-1β and 
IL-18 were increased in INRs after HIV stimulation. In agreement with the 
increased expression of NLRP3, IL-1β and IL18 were increased too in INRs 
suggesting that inflammasome pathway was more induced in these 
patients compared to IRs. Of interest, IFNγ expression, as well as IL-6 
expression, upon HIV stimulation in INRs was significantly lower compared 
to IRs which may due to a deeper impairment of specific antiviral immune 
response in INRs compared to IRs. Next, we decided to evaluate caspase-
1 expression either in unstimulated or LPS- or AT2-treated-HIV-1BaL treated 
cells. In all conditions, a significant increase in caspase-1 expression in 
INRs was observed. Given that caspase-1 is induced by inflammasome 
activation [216], these data further confirm that in INRs inflammasome 
activation is, indeed, higher compared to IRs. In addition, caspase-1 
mediates a form of high inflammatory programmed cell death called 
“pyroptosis” [266]. The higher expression levels of caspase-1 in INRs 
suggest that these patients may be more susceptible to pyropotos is 
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compared to IRs, which could – at least in part – explain the lack of 
immunological recovery during ART. Indeed, according to Doitsh et al., 
caspase-1 activation in HIV-infected individuals may be present even in 
absence of actual productive ongoing viral replication and thus it may lead 
to pyroptosis and cell death even if the settings of ART treatment [314]. 
According to this model, if HIV infects resting and non-permessive CD4+ T-
cells (which account for 95% of all CD4+ T-cells), abortive infection occurs, 
leading to an accumulation of incomplete viral DNA transcripts that are 
detected by IFI16. IFI16 is, in turn, able to assemble into an inflammasome 
and thus to activate caspase-1, which is then able to trigger pyroptosis and 
inflammation. This high inflammatory status and the release of ATP by 
pryototic CD4+ T cells would then be responsible for the activation of other 
inflamamsomes, such as NLRP3, and for new rounds of both pyroptosis 
and inflammation even in absence of ongoing productive HIV replication 
[314]. The authors also reported that this process would take primary place 
in the lymph node, rather than in the blood. Indeed, the authors noticed that 
even though quiescent blood CD4+ T-cells supported HIV entry and fusion, 
they were highly resistant to pyroptotic cell death [292] and this is probably 
due to their deeper state of cellular rest. Deeper resting state would lead to 
fewer incomplete reverse transcripts following abortive infections and thus 
of lower expressions of PRRs, such as IFI16. Nevertheless, we were able 
to observe increased caspase-1, NLRP3, IL-1β, IL-18 and IFI16 expression 
in PBMCs from INRs and plasma concentration of caspase-1 and IL-1β 
were higher in INRs as well. This could be due to the fact that we analyzed 
PBMCs, which are a heterogeneous cell population compromising not only 
CD4+ T cells but other lymphocytes and monocytes too. Monocytes are 
known for constitutive caspase-1 expression [318] and release of IL-1β 
upon TLR4 stimulation; therefore the higher expression levels of caspase-
1, NLRP3 and IL-1β could depend on increased activation of monocytes in 
INRs compared to IRs. Of note, the array data of LPS-stimulated PBMCs, 
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showed a significant up-regulation of TLR4 in INRs compared to IRs. In 
addition, expression levels of caspase-4 and caspase-5, involved in the 
“non-canonical” activation of NLRP3 inflammasome in human monocytes, 
were higher, even though not statistically significant, in INRs compared to 
IRs [319]. These observations could be of high interest because they 
suggest that monocytes in INRs are much more activated than IRs and 
thus probably contributing to a higher inflammation and immune activation 
status observed in INRs. All together these data suggest that 
inflammasome pathway and possibly pyroptosis are upregulated in INRs 
and could likely contribute to the lack of immune recovery observed in 
these patients. Interestingly, very preliminary data from Doitsh et al., 
suggest that in HIV-infected patients, caspase-1 can be detected in the 
lymph nodes at higher levels compared to uninfected individuals even 
under HAART [320], further supporting our evidences. Even more 
interestingly, a recent report investigating caspase-1 and caspase-3 plasma 
levels in a CD4high group (CD4+ T cells > 450 cells/μl) and in a CD4low group 
(CD4+ T cells < 250 cells/ul), showed that while in the CD4high group 
caspase-1 and caspase-3 levels increased rapidly and decreased within a 
short time during early HIV-1 infection, levels in the CD4low group were 
increased after 1 year of HIV-1 infection [296]. These data appear to be in 
agreement with our observations of higher levels of caspase-1 expression 
in INRs and strongly suggest an involvement of caspase-1 in the regulation 
of cell death and inflammation in these patients. We have also observed 
increased plasma levels of IL-1β in INRs even though it was not significant. 
Nonetheless, these evidences further support the idea that inflammasome 
activation is higher in INR patients.  
We could not detect any differences in IL-6 plasma levels between INRs 
and IRs. This is somewhat surprising because IL-6 is one of the most 
important pro-inflammatory cytokines and it has been associated with AIDS 
progression and non-AIDS related morbidity [48]. It was therefore 
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reasonable to expect higher IL-6 levels in INRs. Despite this, a recent 
report from Tincati C. et al. on IL-6 plasma levels in IRs and INRs are in 
agreement with our data, indicating that probably this cytokine does not 
play such a central role in INRs’ higher immune activation status [313]. In 
agreement with our data, there is also a very recent report by Stiksrud B. et 
al. The authors performed an extensive analysis on plasma inflammatory 
markers in INRs and IRs and could not find increased IL-6 levels in INRs 
[202]. It has been demonstrated that inflammasomes are also able to 
regulate cellular immune response by stimulating the differentiation of CD4+ 
T cells into Th1 or Th17 T cells [251]. Given the lack of consistent 
evidences about the role of peripheral Th17 T cells in HIV pathogenesis 
and immune activation, we decided to evaluate this cellular subset in 
PBMCs from IRs and INRs. Interestingly, we observed significant increased 
levels of Th17 T cells in INRs, even in the settings of HIV-1 or LPS 
stimulation. Th17 T cells are known for their pro-inflammatory role, 
therefore the increased levels in INRs could underlie some inflammatory 
processes that could elicit immune activation. These data are interesting 
because it has been extensively demonstrated that intestinal Th17 T cells 
are particularly sensitive to HIV infection and are rapidly depleted upon 
primary infection, contributing to the disruption of the intestinal mucosal 
barrier and to microbial translocation. It is therefore of interest that we 
found Th17 T cells to be increased in INRs. Our data are somewhat in 
agreement with Girard A. et al. The authors reported increased frequencies 
of β7+ Th17 T cells in INRs compared to IRs and healthy controls [204]. 
β7+ is a gut homing marker and the authors suggested that mucosal Th17 
T cells are recruited to the Gut-Associated Lymphoid Tissue (GALT) due to 
previous depletion; once in the GALT, these cells would become more 
sensitive to infection and this condition would lead to an altered Th17/Treg 
ratio and a disturbed intestinal homeostasis, which could lead to microbial 
translocation. Next, we therefore decided to focus on microbial 
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translocation. In recent years, microbial translocation has been considered 
one of the main drivers of immune activation and chronic inflammation in 
HIV-infected individuals [321]. For this reason, our hypothesis was that 
higher levels of microbial translocation in INRs could be responsible for the 
higher inflammasome activation that we observed in these individuals. To 
test this hypothesis we quantified plasma levels of LPS and sCD14, which 
are two of the main markers of microbial translocation. Surprisingly, we 
could not detect any differences between the two groups of patients, 
suggesting that microbial translocation is not the main driver of 
inflammasome activation in these patients. Interestingly, Tincati C. et al 
data is in agreement with ours: they reported comparable levels of LPS and 
sCD14 between HIV-infected individuals which recover or not CD4+ T cell 
count [313]. Stiksrud et al., recently measured LPS and sCD14 in a cohort 
of INRs and IRs and they could not detect any differences between the two 
groups either, in agreement with our results [202]. Moreover, it has been 
suggested that probably while microbial translocation markers have been 
shown to predict clinical outcome in untreated HIV infection, their use in 
HAART-treated patients may not be as accurate [189]. Given these 
premises, it is therefore tempting to speculate that higher inflammasome 
activation rates observed in INRs may probably be due to residual HIV 
defective replication, which would, in turn, lead to inflammation, immune 
activation and cell death. Indeed, despite full suppressed viremia during 
HAART, there is an important ongoing debate on its real efficacy at 
completely inhibiting viral replication. As it has been reviewed so elegantly 
by J. Martinez-Picado and S. G. Deeks, while there is ample evidence that 
modern HAART is effective at inhibiting viral replication, there is also ample 
evidences of the contrary: even during HAART, HIV may still replicate at 
low levels and perhaps only in a subset of individuals [322]. Indeed, there 
have been evidences that cell-to-cell transmission of HIV is not inhibited by 
HAART and, even more interestingly, cell-to-cell transmission effectively 
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triggers pryoptotic cell death of lymphoid-tissue-derived CD4+ T cells[293], 
[314], [323]. Therefore if antiretroviral drugs only sub-optimally inhibit cell-
to-cell transmission, inflammation and depletion of CD4+ T cells would still 
take place in spite of suppressed viremia. In addition, antiretroviral drug 
distribution is not homogenous with higher concentration reported in 
PBMCs, and lower concentration in certain tissues, such as lymph nodes 
and ileal and rectal mononuclear cells. These anatomical sites represent 
“immune sanctuaries”, in which the virus could still be able to replicate. It 
should also be taken into consideration that antiretroviral drugs are also 
mostly ineffective at clearing cells harboring latent HIV. Nonetheless, 
further evidences are necessary to fully prove that in INRs, HIV replication 
– being it defective or productive – still happens and it should be of primary 
interest to evaluate it as it could explain many of the immunological 
features observed in these patients.  
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In conclusion, we observed that increased immune activation levels and 
percentage of Th17 T cells and higher levels of inflammasome and 
caspase-1 expression could be detected in INR patients. The up-regulation 
of these pro-inflammatory mechanisms may plausibly contribute to the 
persistent immune activation that characterize INRs. Notably, higher levels 
of caspase-1 expression are likely to induce CD4+ T cell loss via pyroptosis, 
contributing to the unsatisfactory CD4+ T cell recovery observed in INRs. 
We could not detect any differences in microbial translocation markers 
between INRs and IRs and therefore microbial translocation is unlikely to 
be one of the main drivers of inflammasome activation. It is reasonable to 
speculate that other mechanisms are involved in triggering inflammasome 
upregulation in these patients. It is tempting to speculate that residual HIV 
replication may be at fault, however more experimental evidences are 
needed to prove this hypothesis. In the future, it would be of high interest to 
further characterize the inflammasome pathway upon HIV stimulation in 
macrophages and in lymphoid CD4+ T cells from IR and INR HIV-infected-
ART treated patients and to evaluate the eventual residual HIV replication 
in these patients.  
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